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ABSTRACT
Targeting Calcium Homeostasis for the Treatment of Multiple Myeloma
Osama M. Elzamzamy
Multiple myeloma (MM) is a hematological malignancy characterized by the neoplastic
proliferation of the plasma cells. MM is a relatively rare cancer that accounts for about 1.8% of all
cancers and is the second most common hematologic malignancies, and despite the advancement
from untreatable to treatable malignancy, it is yet incurable. Calcium ions (Ca2+) play an important
role as second messengers in regulating a plethora of physiological and pathological processes,
hence cytoplasmic Ca2+ is tightly regulated with strict spatial and temporal control to initiate,
maintain, and terminate appropriate signaling pathways and phenotypes including cellular
proliferation, cell cycle control, migration, gene expression, muscle contraction, metabolism, and
cell death. Multiple Ca2+ pumps and channels exist in the cell to tightly regulate cytoplasmic Ca2+
levels. The plasma membrane Ca2+ transport ATPase (PMCA), and the Na+/Ca2+ exchanger
(NCX) are present on the plasma membrane, the mitochondrial Ca2+ uniporter (MCU) are located
on the mitochondrial membrane, and the sarcoplasmic reticulum/endoplasmic reticulum Ca2+ATPase (SERCA) pump, the 1,4,5-triphosphate receptor (IP3R) and ryanodine receptor (RyR)
channels are expressed on SE/ER membranes, all these channels work seamlessly to regulate and
redistribute Ca2+ levels among various cellular compartments. The major Ca2+ regulatory pathway
in non-excitable cells is the Store-Operated Ca2+ Entry Pathway (SOCE) and one its major
contributors is TRPC1. TRPC1 is a member of the TRP protein superfamily and a potential
modulator of store-operated Ca2+ entry (SOCE) pathways. While TRPC1 is ubiquitously expressed
in most tissues, its dysregulated activity may contribute to the hallmarks of various types of
cancers, including breast cancer, pancreatic cancer, glioblastoma multiforme, lung cancer, hepatic
cancer, multiple myeloma and thyroid cancer. Our group has developed a novel cyclic peptide
referred to as MTI-101 for the treatment of MM. MTI-101 is derived from a 10 D-amino acids
peptide HYD1, which was discovered to block cancer cell adhesion to extracellular matrix. It was
previously reported that acquired resistance to HYD-1 correlated with repression of genes involved
in store operated Ca2+ entry (SOCE): PLCβ, SERCA, ITPR3, and TRPC1 expression. We sought
to determine the role of TRPC1 heteromers in mediating MTI-101 induced cationic flux. Our data
indicate that consistent with activation of TRPC heteromers, MTI-101 treatment induced Ca2+ and

Na+ influx. However, replacing extracellular Na+ with NMDG did not reduce MTI-101-induced
cell death. In contrast, decreasing extracellular Ca2+ reduced both MTI-101-induced Ca2+ influx as
well as cell death. The causative role of TRPC heteromers was established by suppressing STIM1,
TRPC1, TRPC4 or TRPC5 function both pharmacologically and by siRNA, resulting in a
reduction in MTI-101-induced Ca2+ influx. Mechanistically MTI-101 treatment induces trafficking
of TRPC1 to the membrane and co-immunoprecipitation studies indicate that MTI-101 treatment
induces a TRPC1-STIM1 complex. Moreover, treatment with calpeptin inhibited MTI-101induced Ca2+ influx and cell death indicating a role of calpain in the mechanism of MTI-101induced cytotoxicity. Finally, components of the SOCE pathway were found to be poor prognostic
indicators among MM patients, suggesting that this pathway is attractive for the treatment of MM.
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Chapter 1 Calcium Signaling in Health and Disease
1.1 Multiple Myeloma
Multiple myeloma (MM) is a hematological malignancy characterized by the neoplastic
proliferation of the plasma cells. The neoplastic proliferation of plasma cells containing
monoclonal (M) protein immunoglobulin is a hallmark of multiple myeloma (MM). The plasma
cells proliferate in the bone marrow, causing osteolytic lesions, osteopenia, and/or pathologic
fractures.
1.1.1. Epidemiology
MM is a relatively rare cancer that accounts for about 1.8% of all cancers and slightly more than
17% of hematologic malignancies. According to the US Surveillance, Epidemiology, and End
Results (SEER) registry, 34,920 new cases and 12,410 deaths from MM are expected in the United
States in 2021 [1, 2]. Worldwide, MM is responsible for about 160,000 cases and 106,000 deaths
per year. There has been an increased incidence of MM overtime, this is most likely due to
increased use of routine laboratory testing, increased awareness of the disease, and increased
availability and use of medical facilities, especially among the elderly [5].
MM is significantly prevalent in men than in women (ratio of approximately 1.4:1). It often occurs
in elderly population with the median age at diagnosis of 65 to 74 years. Only 10% are younger
than 50 years, and 2% are younger than 40 years old at the time of diagnosis [6, 7]. MM affects
people of all races, but the incidence rate is two to three times higher in African Americans and
Black populations than in White populations [7, 8].
1.1.2. Risk factors
The level of body fat plays a role in cancer development, a study have showed that low body mass
index reduces the risk of development of eight types of cancer liver, gallbladder, pancreas, thyroid,
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ovary, gastric cardia, and multiple myeloma [9, 10]. Historically, Agent Orange exposure has also
been linked to the development of MM, where patients with monoclonal gammopathy of
undetermined nature (MGUS) that have been exposed to Agent Orange have a higher chance of
progressing to MM [11]. Familial history of MM also provides a risk of passing to the next
generations with an estimated 3 familial cases per 1000 MM patients [20-34], a small percentage
of cases are familial. People who have a first-degree relative who has MM have a 3.7-fold
increased chance of developing MM [12, 13]. In a study of 15 families with MM clustering, ten of
them had MM clustering in siblings, in 7 out of the 10 families, the same monoclonal
immunoglobulin G (IgG) kappa pattern was found [14]. Furthermore, persons with a common
variance at the genetic loci 3p22.1 or 7p15.3 (odds ratios of 1.32 and 1.38, respectively) have a
higher risk of developing MM as was detected by a genome-wide association analysis (GWAS)
[15]. These genetic variances account for 5% of the familial risk, and have no clinical implications
as indicated by a low hazard ratio.
1.1.3. Clinical Presentation and Pathological Features
The diagnosis of MM is suspected when the patient is presented with one of the following clinical
presentations; Bone pain with lytic lesions discovered during routine radiology imaging,
unexplained anemia, along with other malignancy suggestive signs and symptoms, increased total
serum protein and monoclonal proteins in the serum or urine, asymptomatic or incidentally
discovered hypercalcemia, and/or, nephrotic syndrome due to immunoglobulin light chain
amyloidosis or acute renal failure with bland urinalysis [7].
Most MM patients are presented with increased levels of the monoclonal (M) proteins secreted by
the malignant plasma cells and detected by serum FLC (Free Light Chain) analysis, or by SPEP
(protein electrophoresis of the serum, or UPEP (protein electrophoresis of the urine) following a
24-hour urine collection accompanied by immunofixation of the urine and serum [7]. Depending
2

on the test used, the specificity increases. The SPEP analysis detects a localized band or a peak in
80% of patients, and is increased to 90% sensitivity with serum protein immunofixation. FLC
analysis or UPEP along with previous studies increase the sensitivity of M protein detection to
97%. The absence of M protein with all these tests indicates nonsecretory myeloma [7]. The
increase in the monoclonal M protein production by the malignant plasma cells results in
suppression of uninvolved immunoglobulins (IgM, IgA, etc.) is hypogammaglobulinemia and is
named ‘immunoparesis’. Immunoparesis have been reported to be associated with shorter
progression free survival (PFS) in a study conducted in the Danish population [16]. Moreover, the
extent of immunoparesis has been shown to be a poor prognostic indicator for Monoclonal
Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
as they advance to MM [17].
The diagnosis of MM requires the presence of; 1) clonal plasma cells in the bone marrow ≥10 %
confirmed by kappa/lambda chain restriction by flow cytometry, immunofluorescence or
immunohistochemistry, and the sample has to be from a bone marrow core specimen. 2) Tissue or
organ impairment defined by increased calcium levels, renal insufficiency, anemia, and bone
lesions, and are abbreviated as CRAB. 3) Detection of biomarkers associated with end-organ
damage including; a) 60%≥ clonal plasma cells in the bone marrow, b) ratio of involved to
uninvolved immunoglobulins FLC ration equal to or more than 100, c) more than one focal lesion
detected by MTI [18-23].
1.1.4. Treatment
MM has advanced from untreatable to treatable malignancy, but yet incurable, with treatment
options advancing over the decades. The first discovered treatment was the autologous stem cell
transplant (ACST) discovered in the 1980s’[24]. ACST was followed by the discovery of novel
agents including thalidomide and lenalidomide (IMID’s).
3

Later, treatment options further

improved with the discovery of the proteasome inhibitors (PIs) lid by bortezomib. More recently,
elotuzumab and daratumumab categorized as monocolonal antibodies, and Panobinostat the
histone deacetylating agent has been approved by the US Food and Drug Administration [25].
The treatment decision for MM is based on the stage of the disease. The staging of MM is
determined using the International Staging System (ISS) guidelines and the Revised-ISS (Table 1)
[26, 27]. Based on the National Comprehensive Cancer Network (NCCN) Multiple Myeloma
Guidelines, the therapy general principals is that MM patients should undergo a triplet regimen as
a standard approach, however, patients that can’t tolerate the triplet regimen could be started on 2drug regimen. If a patient is undergoing hematopoietic cell transplant, they should avoid
myelotoxic agents including alkylating agents and nitrosoureas to avoid compromising stem cell
reserve, furthermore, harvesting peripheral blood stem cells should be considered prior to initiating
the treatment on lenalidomide and/or daratumumab [27].
Stage International Staging System (ISS)

Revised-ISS (R-ISS)

I Serum beta-2 microglobulin <3.5 mg/L

ISS stage I and standard-risk chromosomal
abnormalities by FISH and Serum LDH ≤
the upper limit of normal

Serum albumin ≥3.5 g/dL

II Not ISS stage I or III

Not R-ISS stage I or III

III Serum beta-2 microglobulin ≥5.5 mg/L

ISS stage III and either high-risk
chromosomal abnormalities by FISH or
Serum LDH > the upper limit of normal

Table 1. The international Staging System (ISS) and Revised-ISS for defining MM stages [27].
The NCCN guidelines for treatment of MM is versatile and expands to include primary therapy
for transplant candidates (13 regimens) and non-transplant candidates (11 regimens) , and their
4

maintenance therapy (4 and 3 regimens for transplant and non-transplant patient, respectively),
the guidelines also include alternative combinational therapies for patients previously treated for
MM [27]. Despite all the advancements in the various combinational therapies for MM, the disease
remain incurable and new therapeutic strategies presents as unmet need that must be addressed.
1.2 Calcium Homeostasis
1.2.1. Introduction
Intracellular free Ca2+ concentration is extensively distributed throughout the cell, varying from
one compartment to another. Under resting conditions, the cytoplasmic [Ca2+] ([Ca2+]c) is at 100
nM, around 104 times lower than [Ca2+] in the extracellular matrix. Both the nuclear and the
mitochondrial compartments (Ca2+) have similar ([Ca2+]n) levels in the cell as compared to the
cytoplasm [28]. The main internal Ca2+ stores compartment inside the cell is the endoplasmic
reticulum (ER), and is capable of accumulating Ca2+ and maintaining a higher [Ca2+] concentration
than the cytoplasm (about 1-5×10-4 M). In muscle cells, the sarcoplasmic reticulum (SR) is the
primary Ca2+ storage [29, 30].
Multiple Ca2+ pumps and channels exist in the cell to tightly regulate [Ca2+]c levels. The plasma
membrane Ca2+ transport ATPase (PMCA), and the Na+/Ca2+ exchanger (NCX) are present on the
plasma membrane [31]. The mitochondrial Ca2+ uniporter (MCU) are located on the mitochondrial
membrane [32, 33]. While, the sarcoplasmic reticulum/endoplasmic reticulum Ca2+-ATPase
(SERCA) pump, the 1,4,5-triphosphate receptor (IP3R) and ryanodine receptor (RyR) channels
are expressed on SE/ER membranes [34, 35]. In a resting state, [Ca2+]c is maintained at low levels
by the plasma membrane Ca2+ transport ATPase (PMCA) and the Na+/Ca2+ exchanger (NCX)
[36]. When [Ca2+]c is increased, the Ca2+ is up taken into the ER and SR by SERCA pump and to
a lesser extent into the mitochondria by the MCU [37, 38]. The removal of elevated [Ca2+] results
in homeostatic [Ca2]c control. [Ca2+]c levels could rise from 100 nM to 1µM usually in a steep
5

fashion followed by a decline, forming cytoplasmic Ca2+ spikes or repetitive Ca2+ oscillations, this
is enhanced by the positive and negative feedback of Ca2+ effects facilitating the synchronized
activation and deactivation of Ca2+ channels and the homeostatic Ca2+ removal mechanisms.
Multiple factors contribute to the increased [Ca2+]c levels including membrane depolarization,
extracellular molecular binding and intracellular signals. Although the result is an increase in
[Ca2+]c, each stimulus activates a different pathway depending on the tissue where the cell is
present, further, Ca2+ regulated channels and proteins respond to different thresholds and patterns
depending on their functionality; the NCX and MCU have low affinity to Ca2+ and high
conductance rate (150-300 Hz for NCX) limiting larger cytoplasmic Ca2+ transients, while SERCA
and PMCA have high affinity to Ca2+ and low conductance rate (≈10 and ≈30 Hz, respectively)
responding to modest elevations in cytoplasmic Ca2+ levels [38]. Myriad of cellular functions are
regulated by [Ca2+]c, hence is tightly regulated with strict spatial and temporal control to initiate,
maintain, and terminate appropriate signaling pathways and phenotypes including cellular
proliferation, cell cycle control, migration, gene expression, muscle contraction, metabolism, and
cell death (Figure 1) [4, 39].
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Figure 1: Intracellular calcium homeostasis. Intracellular calcium levels are tightly regulated
within a narrow physiological range. Cellular calcium influx through the plasma membrane is
largely mediated by receptor-operated calcium channels (ROCC), voltage-operated calcium
channels (VOCC), store-operated calcium channels (SOCC) and, under exceptional
circumstances, the sodium/calcium exchanger (NCX). Under physiological conditions, NCX is
mainly involved in calcium efflux; however it can also reverse its mode of operation (reverse
mode exchange) thereby contributing to calcium influx, especially during strong depolarization
and in the presence of high intracellular sodium concentrations. Calcium may also be released
into the cytoplasm from the endoplasmic reticulum, through inositol-1,4,5-trisphosphate (IP3R)
and ryanodine receptors (RYR). Different systems operate within the cell to counterbalance the
cytosolic calcium increase. Specifically, the plasma membrane calcium pump (PMCA), NCX,
and sarcoendoplasmic reticulum calcium ATPase (SERCA) participate in restoring
physiological calcium levels. The excess of intracellular calcium can also be taken up by
mitochondria through the mitochondrial calcium uniporter (MCU). Calcium can be released
back into the cytosol through the activity of mitochondrial NCX (mNCX), which can also
reverse its mode of operation allowing the access of calcium ions into the mitochondrial matrix.
Recently, the mitochondrial hydrogen/calcium exchanger (mHCX) has been proposed to be an
electrogenic 1 : 1 mitochondrial calcium/hydrogen antiporter that drives the uptake of calcium
into mitochondria at nanomolar cytosolic calcium concentrations. PTP, permeability transition
pore; MMCA, mitochondrial membrane Ca2+ATPase [4] (Republished from Magi, S., et al.,

Intracellular Calcium Dysregulation: Implications for Alzheimer's Disease. Biomed Res Int, 2016.
2016: p. 6701324. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium)

1.2.2. The Store-Operated Calcium Entry Pathway (SOCE)
The store-operated Ca2+ entry pathway (SOCE) is a major Ca2+ entry pathway in non-excitable
cells and SOCE activity is known to modulate insensitivity to antigrowth signals via multiple
routes, as reviewed by Prevarskaya et al [40]. There are numerous channels and transporters that
regulate Ca2+ levels and deciphering the role and interplay of individual members in facilitating
tumor progression remains challenging. There is a great deal of controversy surrounding the role
of TRPC1; while some reports suggest it is an ion channel, other reports suggest that TRPC1 alone
is not sufficient to form an ion channel, and functions as a modulator of other TRPC channels.
Additionally, the expression of TRPC1 as a prognostic marker in cancer appears to be context
specific as TRPC1 expression has been reported to be associated with poor clinical outcomes for
certain types of cancers, while in other indications it is reported to be associated with improved
7

outcomes. This review will focus on the role of TRPC1 expression as a determinant of SOCE and
cancer progression.
The transient receptor potential (TRP) ion channels were first discovered in Drosophila
melanogasler by studying photo-transduction [41]. The TRP protein superfamily shares
similarities in structure to the parent Dorsophila TRP and were initially classified into 3
subfamilies TRP-Canonical, TRP-Vanilloid, and TRP-Melastatin (TRPC, TRPV, and TRPM
respectively) [42]. Later, the TRP superfamily was classified into 7 subfamilies; TRPClassical/Canonical (TRPC), TRP-Vanilliod (TRPV), TRP-Melastatin (TRPM), TRP-Ankyrin
(TRPA), TRP-Polycystin (TRPP), TRP-Mucolipin (TRPML). The non-mechanoreceptor potential
C-TRP (TRPN), is comprised of approximately 30 members [43]. Except for TRPM4 and TRPM5,
which are Ca2+-activated monovalent-selective cation channels [44, 45], TRP family members are
non-selective channels that are permeable to Ca2+ to varying degrees [43]. TRP channels generally
share structural similarities that include six-transmembrane domains and the proteins typically
assemble as homotetrameric or in some cases heterotetrameric channels summarized by Strubing
and colleagues [46].
In addition to TRP channels, the SOCE mechanism of action is dependent on the depletion of the
endoplasmic reticulum (ER) Ca2+ stores through ryanodine receptors (RyR) or inositol 1,4,5trisphosphate receptors (IP3R) [47, 48]. SOCE is regulated by agonist binding surface receptors,
including G-protein coupled receptors (GPCR) or receptor tyrosine-kinases (RTK), activating
phospholipase Cβ (PLCβ) via Gq/11 and PLCγ via RTK mediated signaling [30, 49]. This results
in the enzymatic cleavage of plasma-membrane phosphatidylinositol 4,5-bisphosphate (PIP2) into
IP3 and diacylglycerol (DAG). The depletion of Ca2+ stores from the ER is sensed by the
transmembrane protein stromal interaction molecules (STIM1 and STIM2), as Ca2+ dissociates
from the EF domain of STIM1 and/or STIM2[50]. STIM molecules multimerize and translocate
8

to ER-PM junction to form puncta that co-assemble with any or all of three Calcium-ReleaseActivated Calcium (CRAC) channel subunits Orai1/2/3. This protein-protein interaction between
STIM and Orai results in the sustained opening of the highly Ca2+-selective CRAC channels that
allow for both cytosolic Ca2+ signaling and replenishing of ER stores [30]. Additionally, in some
cell types, STIM1 may intersect with Orai1 and members of TRPC subfamily by its reported
capability to directly interact with TRPC1, TRPC4, and TRPC5, and indirectly with TRPC3 and
TRPC6 (Figure 2 A) [51-54].

Figure 2. The Store-Operated Ca2+ Entry pathway (SOCE): A) SOCE is regulated by agonist

binding to G-protein coupled receptors (GPCR) or receptor tyrosine-kinases (RTK), activating
phospholipase Cβ (PLCβ) via Gq/11 and PLCγ via RTK mediated signaling, resulting in the production
of IP3 and DAG from the cleavage of plasma-membrane PIP2. IP3 depletes Ca2+ stores from the ER
through the IP3R which is sensed by STIM1. B) STIM molecules multimerize forming puncta and
translocate to ER-PM junction co-assembling with the CRAC channel subunits Orai1 activating the Ca2+
selective Icrac currents. Further, STIM1 forms STIM1/Orai1/TRPC1 complex activating cation nonselective Isoc currents [3].

The TRPC subfamily consists of seven members (TRPC1-7), and they are known to function as
non-selective cation channels, with permeability to Ca2+, Na+, and K+ [55]. The role of TRPC1 in
SOCE activity has been discussed in a recent report by Dyrda and colleagues, where they reported
that TRPC1 activation is dependent on activation of the Icrac current activated by STIM1 and
comprised of Orai1/2/3 [56]. However, activation of STIM1 doesn’t necessarily activate TRPC1,
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as there are two proposed mechanisms for the store-operated channels activation. The
transmembrane protein STIM1 interacts with Orai1 activating the CRAC channels, with Ca2+
selective Icrac currents [57-60]. STIM1 interacts with TRPC1, forming STIM1/Orai1/TRPC1
complex and activating the SOC channels conducting a cation non-selective Isoc currents [60, 61].
This experimental evidence supports a model in which, following the activation of the SOC
channels, the non-selective cation channels TRPC1, TRPC4, and TRPC5 form heterotetramers as
TRPC1/TRPC4, TRPC1/TRPC5, or TRPC1/TRPC4/TRPC5 become operative to facilitate further
Ca2+ entry (Figure 2 B) [62-64]. TRPC1 has been under study in recent years as a Ca2+ channel in
the SOCE pathway, on the other hand, recent reports have suggested that TRPC1 when expressed
on it is own is not sufficient to form a channel. The role of TRPC1 has been studied extensively in
recent years to investigate its function as a calcium channel or a modulator for other TRPC
channels. Despite all data and studies into TRPC proteins, their mechanism of action remains
poorly understood. Some members of the TRPC subfamily are capable of forming channels when
expressed alone by forming homomers (TRPC4/TRPC4, and TRPC5/TRPC5) [65]. However,
Storch et al. reported that TRPC1 is incapable of forming Ca2+ permeable channel by itself but is
essential in forming heteromers with all other members of the TRPC subfamily [66]. Further, they
reported a decrease in Ca2+ permeability in heteromeric complexes containing TRPC1, but the
effect of TRPC1 in Ca2+ entry and as a member of the SOCE pathway is tissue dependent.
The role of Ca2+ signaling through the SOCE pathway involving STIM1 and Orai1 has been
reported previously to affect prognosis of cervical, colorectal, breast, esophageal, multiple
myeloma, and lung cancers by affecting tumor growth, proliferation, metastasis, and survival [6770].
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1.2.3. Activation of SOCE pathway for inducing cell death in cancer
Cancer requires robust Ca2+ signaling to support proliferation, invasion and metastasis, whereas
excessive Ca2+ levels lead to apoptosis and cell death, Both the suppression and enhancement of
the SOCE pathways may be exploited for treatment of cancer. In Triple negative breast cancer
(TNBC), Grant et al. reported that TRPC1 and TRPC4 were overexpressed in some TNBC cell
lines. For example, the Hs578T TNBC cell line showed high expression levels of TRPC1 and
TRPC4 compared to the MD-MB-231 TNBC cell line, and the BT-549 TNBC cell line had high
levels of TRPC4 when compared to MD-MB-231 cell line [71]. The higher TRPC expression
levels in these cancer cells may render these cells more vulnerable to therapeutic strategies aimed
at eliciting Ca2+ overload and cell death through channel agonists rather than pharmacological
inhibition to reverse hallmarks of cancer.
Support of Ca2+ overload being a vulnerability for cancer is that TNBC cell lines with increased
TRPC4 and TRPC5 showed increased sensitivity to the TRPC4 and TRPC5 activator englerin A
(EA) compared to cell lines with reduced expression [71]. Interestingly, the expression of TRPC4
and TRPC5 alone did not yield sensitivity to EA-induced and Ca2+-dependent cell death, indicating
the importance of the heteromeric formation of TRPC members. Although TRPC1 levels in BT549 cells were comparable to the EA-resistant cell line HCC1806, BT-549 cells showed increased
sensitivity to EA-induced Ca2+ entry and cell death when compared to Hs578T, when TRPC4 alone
is predominantly and highly expressed. A possible explanation for this is the shift of the
heteromeric TRPC1/TRPC4 channel towards more Na+ flux [66]. In renal cell carcinoma (RCC),
A498 RCC cell lines responded to englerin A by elevation of intracellular Ca2+ levels and followed
by cell death The Ca2+ entry was due to activation of TRPC4 channels as was demonstrated by
patch-clamp studies. Further, while the expression of only TRPC1 did not contribute as a Ca2+
channel to the englerin A-induced Ca2+ overload and cell death, the co-expression of TRPC1 and
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TRPC4 and their heteromeric formation reproduced the same Ca2+ entry currents in HEK293 cells
[72].
These findings corroborate the importance of TRPC1 expression for the overall functionality of
the SOCE pathway. Our laboratory has shown that the novel cyclic peptide referred to as MTI-101
induces a robust and sustained increase in intracellular Ca2+ levels in multiple myeloma cells lines
[73, 74]. Emergence of resistance to chronic exposure of increasing concentrations of MTI-101 in
the multiple myeloma H929 cell line correlated with decreased expression of the IP3 receptor,
SERCA pump, PLCβ, TRPC1 and TRPM7. Treatment with the pharmacological inhibitor 2-ABP
attenuated MTI-101-induced Ca2+ influx, a finding that correlated with decreased cell death. U266
and MM1.s myeloma cells with reduced expression of TRPC1 using shRNA strategies showed a
reduction in MTI-101 induced cell death [73]. Further studies are required to determine the role of
TRPC1 in mediating MTI-101 induced Ca2+ entry and whether MTI-101-induced activity is
dependent on activation of TRPC1 heteromers and regulation of the SOCE pathway, thereby
allowing for sustained Ca2+ influx and leading to caspase-independent cell death [74].
Interestingly, MTI-101 was found to be more active in primary specimens obtained from myeloma
patients relapsing on standard of care agents. Together, these data suggest that stimulating Ca2+
overload maybe a unique vulnerability to cancer cells, as experimental evidence indicates that
cancer cells remodel Ca2+ handling pathways to favor Ca2+ influx required to facilitate the
hallmarks of cancer.
1.2.4. SOCE Pathway Gene expression and their Clinical Outcomes
As outlined above, several TRPC members have been studied and implicated in the promotion of
cancer through tumor cell proliferation, migration, invasion, and survival, as observed in lung
cancer, malignant glioma, neuroblastoma, renal cell carcinoma, hepatoma, thyroid cancer, colon
cancer, and breast cancer [75-82]. With respect to TRPC1, the screening of patient specimens as
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well as the mining of large data sets have yielded several clinically relevant insights in patients
with tumors expressing TRPC1. Faouzi et al. reported TRPC1 to be expressed in all examined 17
data sets of breast cancer specimens, with no specific clinical significance [82]. Azimi et al.
reported the TRPC1 expression levels in a data set from the University of North Carolina of 855
breast cancer patients, classified and reported based on the 50-signature genes subtype
classification known as PAM50 [83, 84]. The claudin-low breast cancer subtype exhibited the
highest TRPC1 expression levels compared to other subtypes. Further, in TNBC, the mesenchymal
subtype showed the highest expression level of TRPC1, and the basal subtype with lymph-node
metastasis showed worsened prognoses associated with high TRPC1 expression levels [84]. In
lung cancer, SOCE components including STIM1, Orai1 and TRPC channels have been examined
in a dataset of more than 2,000 cases. While TRPC1 had no effect on the risk of lung cancer, two
variants of TRPC4 namely (rs9547991 and rs978156), and one variant of TRPC7 (rs11748198)
were associated with increased risk of lung cancer compared to control subjects [75]. TRPC1
plasma membrane levels have been reported to be low when in inactive status, being located in
close proximity to the plasma membrane. Transfer to the plasma membrane is dependent on Ca2+
signals generated by STIM1-Orai1 activation [85]. Thus, membrane localization may be an
important factor linking SOCE and TRPC1 functions, even if expression levels may not change.
Considering the function of TRPC1, it is feasible that quantification of membrane staining of
TRPC1 may lead to increased sensitivity as a prognostic indicator in cancer. Taken together,
targeting the increased expression of TRPC1 and other SOCE pathway proteins could aid in
discovering novel cancer therapeutics, especially for relapsed patients on currently available
treatment regimens.
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1.3 HYD1 and MTI-101
1.3.1. HYD1 and the more potent cyclic peptide MTI-101
HYD1 is a peptide that was discovered to block cancer cell adhesion to extracellular matrix in
epithelial carcinoma cells [86, 87]. It is 10 D-amino acid with the sequence KIKMVISWKG,
further, it has been reported to induce cell death in U266, 8226, and H929 MM cell lines, but not
in the hematopoietic CD34+ progenitor cells or PBMCs (peripheral blood mononuclear cells), the
HYD1-induced cell death is associated with loss of mitochondrial membrane potential, ATP
depletion, and ROS production, and not apoptotic or autophagic in nature, being caspaseindependent [86, 87]. Following the discovery of HYD1-induced caspase independent cell death,
Gebhard and colleagues discovered the minimally active truncated core region in HYD1 to be
(MVISW). The active core was transformed into a cyclic peptide using a β turn promoter scaffold
backbone with the addition of 3 lysines, creating a water soluble, more potent drug named MTI101 [74]. The newly formed cyclic peptide MTI-101 had the optimized sequence NLeVVAW
(Figure 3). MTI-101 showed to be more potent than HYD1 in multiple myeloma cell lines U266
and NCI-H929, with 87% percent reduction in the IC50 (63.9 µmol/L ± 6.0 vs. 8.38 µmol/L ± 0.9
for HYD1 and MTI-101, respectively) in NCI-H929, and 75% reduction in the IC50 in U266
(89.03 µmol/L ±

18.6 vs. 22.10 µmol/L ± 4.24 for HYD1 and MTI-101, respectively).

Furthermore, MTI-101 showed cross-resistance to the in-house created HYD1-resistant H929-60
cell line, along with a similar caspase-independent cell death. MTI-101 treatment resulted in
reduction in ATP levels, and increased ROS production, going along the lines with what was
previously reported with HYD1 [74, 88].
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Figure 3. MTI-101 Molecular Structure NLeVVAW [74] (Reprinted from Molecular Cancer
Therapeutics, 2013,volume 12, issue 11, 2446-58, Anthony W. Gebhard,Priyesh Jain,Rajesh R. Nair,Michael
F.Emmons,Raul F. Argilagos,John M. Koomen,Mark L.McLaughlin,Lori A. Hazlehurst, MTI-101 (Cyclized HYD1)
Binds a CD44 Containing Complexand Induces Necrotic Cell Death in Multiple Myeloma, with permission from
AACR)

To further define binding partners to HYD1 and MTI-101, Biotin-conjugated HYD1 and MTI101, CD44 was found in complex associated to Biotin-HYD1 and Biotin-MTI-101 analyzed by
LC/MS-MS and Western Blot. To further assess the role of CD44 as a binding target and as an
initiator of the death signal by HYD1, a concentration-dependent increase in binding to
NeutraAvidin-coated plates with Biotin-HYD1 to recombinant CD44. It was also reported that
overexpressing CD44 in the cell line RPMI-8266, where there is a minimal basal expression level
of CD44, resulted in increased binging to FAM-HYD1, albeit, there was no significant increase
in cell death [74]. These date indicated that while CD44 is not a rate-limiting step in the
HYD1/MTI-101 induced cell death, it could play a role in the lateral or downstream cell death
signaling. Furthermore, reducing CD44 expression by siRNA contributed to caspase-3 cleavage
and apoptotic cell death when compared the non-silencing siControl, indicative of CD44 role in
multiple myeloma cell survival, which positions CD44 as a valid target for MM targeting treatment
[74]. To address whether MTI-101 treatment activates a CD44-dependant signaling cascade.
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Gebhard and colleagues examined the binding partners to CD44 following MTI-101 treatment in
U266 and NCI-H929 cell lines, using co-immunoprecipitation studies. They reported an increased
binding of the focal adhesion tyrosine kinase protein Pyk2 to CD44, in both cell lines, moreover,
there was an increased activation of Erk/Map kinase pathways, in U266 and NCI-H929.
Historically, apoptosis is regarded as homeostatic and developmental programmed cell death and
is characterized by a set of morphological characteristics that include chromatin condensation and
nuclear fragmentation, cell shrinkage, plasma membrane blebbing, and the development of
apoptotic bodies. While necrosis has been considered an unregulated, nonspecific kind of cell
death which occurs as a result of nonspecific and nonphysiological stress [89]. However, Yuan
and colleagues reported a form of a complex programmed necrotic cell death, and they named it
necropotosis [90, 91]. Programmed necrosis could be initiated through multiple events; necrotic
cell death may be caused by binding ligands to specific membrane receptors, necrosis can be
regulated by genetic, epigenetic and pharmacological mechanisms, and may contribute to an
embryonic development and adult tissue homeostasis [92]. Necroptosis death signaling cascade
is initiated by the ligand-bound tumor necrosis factor (TNF) receptor 1 (TNFR1), allowing the
formation of a complex (TNFR1 complex 1) containing TRADD (TNFR-associated death
domain), cIAP1 (cellular inhibitor of apoptosis 1), cIAP2, and RIP1 (receptor-interacting protein
kinase 1 (RIP1). Once activated ,RIP1 interacts with RIP3 physically and functionally, inducing
necroptotic signaling complex known as necrosome (Figure 4) [93]. Consequently, activated RIP3
phosphorylates and activates DRP1 (Dynamin-related protein 1), Mfn1 (Mitofusin 1), and Mfn 2.
DRP1 is a cytoplasmic protein that interacts with mitochondrial outer membrane (MOM) causing
mitochondrial fission, loss of membrane integrity, and fragmentation, playing a role in the process
of necroptosis [94, 95].
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Figure 4: Death Signaling By TNFR1: TNF binding TNFR1 allows the formation of TNFR
complex 1, downstream of which the necroptotic death pathway is activated through the activity
of RIP1 and RIP3 [93] ( Reprinted by permission from SPRINGER NATURE, Nature Reviews Molecular
Cell Biology, Vandenabeele, P., et al., Molecular mechanisms of necroptosis: an ordered cellular
explosion. Nat Rev Mol Cell Biol, 2010)

To address whether MTI-101-induced cell death is dependent on the activation of the necroptotic
cell death pathway. Reducing the expression of RIP1, RIP3 and DRP1 by siRNA or
pharmacologically inhibiting DRP1 using mdivi-1 (a known DRP1 inhibitor) significantly
increased the survival of U266 cells when treated with MTI-101 [74]. However, The same results
were not carried over to the cell line NCI-H929, where there was no increased survival with
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inhibition of DRP1, or reducing the expression of RIP1, RIP3, and DRP1. These data suggest that
other pathways contribute to MTI-101 induced cytotoxicity [74]. Lastly, the effect of MTI-101 as
an effective anti-tumor agent against MM. MTI-101 was tested in vivo by injecting 5TGM1 cells
in C57BL/KaLwRijHsd mice. MTI-101 treated mice showed increased survival, along with a
significant reduction in serum κ levels as a single agent, similar to bortezomib, versus control.
Furthermore, the SCID-Hu myeloma mouse model was used to test the effect of MTI-101 on
myeloma without the confounding effect of the systematic disease by engrafting cadaveric fetal
bone into the mammary mouse pad. MTI-101 showed significant increased survival along with
reduction in κ levels versus controls, and no signs of toxicity from MTI-101 was reported [74].
1.3.2. MTI-101 and the Store-Operated Ca+ entry Pathway
To further determine the mechanism of MTI-101 induced cell death. Emmons and colleagues
sought to conduct a comparative gene expression profiling for the HYD1/MTI-101 resistant cell
line H929-60 and its parent cell line NCI-H929 to delineate gene expression differences in
pathways conferring sensitivity and resistance to both compounds [73]. PLCβ, ITPR3, TRPC1,
TRPM7, SERCA, ATP2A3 were downregulated in the resistance cell lines as confirmed by RTPCR. As mentioned earlier, the SOCE pathway is the major Ca2+ entry pathway in non-excitable
cells, and the resistant cell line H929-60 showed downregulation of genes encoding for
components of the SOCE pathway. Interestingly, TRPM7 apart from being a Ca2+ entry channel,
aids in the necroptotic pathway by being a substrate of MLKL, downstream of TNFα and Ripk3
signaling (Figure 5). Consequently, MTI-101 and HYD1 were tested to see if they had an affect
on [Ca2+]c levels in NCI-H929 and H929-60, and data showed that HYD1 and MTI-101 caused
increased [Ca2+]c levels in both cell lines detected by the ratiometric dye fura2-AM, however,
there was a significant reduction in Ca2+ influx by MTI-101 in H929-60 cells vs. NCI-H929. The
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data also showed that [Ca2+]c increase is higher with MTI-101 compared to HYD1, suggesting
that MTI-101 induces MM cell death through Ca2+ overload [73].
As we mentioned previously, IP3R is the calcium channel on the ER membrane allowing Ca2+
release from the ER through IP3 activation. IP3 is a product of plasma membrane PIP2 hydrolysis
by phospholipase Cβ (PLCβ) [49]. The test whether PLCβ is produced downstream of MTI-101
binding and facilitates MTI-101 induced increased [Ca2+]c, the group used PLCβ inhibitor U73122
on NCI-H929 and U266 and were able to decreases MTI-101-induced increased [Ca2+]c levels in
the absence of extracellular Ca2+ [96]. Furthermore, the IP3R blocker 2-APB attenuated MTI-101
induced cell death in U266 and NCI-H929, taken together, these data implicate the ER and SOCE
pathway on MTI-101-induced Ca2+ and cell death [73, 97]. When [Ca2+]c is increased, the Ca2+ is
up taken into the ER and SR by SERCA pump and to a lesser extent into the mitochondria by the
MCU. The removal of elevated [Ca2+] results in homeostatic [Ca2+]c control. The role of the
mitochondria and MCU was addressed by blocking mitochondrial Ca2+ uptake through MCU by
using RU360 [98]. RU360 pretreated MM cells showed significantly increased survival with MTI101 indicating that MTI-101’s induced cell death is partially dependent on the mitochondrial
uptake of increased [Ca2+]c [73].
The role of STIM1 activation downstream of MTI-101 binding was addressed using Total Internal
Reflection Fluorescence (TIRF) microscopy. When ER Ca2+ stores are depleted, Ca2+ is
dissociated from the EF domain in STIM1, allowing it to undergo conformational changes, and
trafficking to the ER/PM membrane space to bind Orai1/2/3 (CRAC channels), leading to Ca2+
influx [30]. In a confined specimen region immediately proximal to the interface between two
media with differing refractive indications, TIRF microscopy exploits the uniqueness of an
evanescent wave or field generated allowing the imaging of fluorophores within 100 nm distance
from the plasma membrane [99]. Following MTI-101 treatment, U266 cells overexpressing STIM1
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mCherry tagged protein were imaged using TIRF, interestingly, STIM1-mCherry fluorescence
intensity increased following 10 minutes treatment of MTI-101 when compared to control (Figure
6). Furthermore, reducing TRPC1 expression using shRNA significantly attenuated MTI-101induced cell death. Taken together, these strongly suggest that the SOCE pathway plays a major
role in the Ca2+ influx induced cell death following MTI-101 treatment.

Figure 5. MTI-101 activates STIM1. (A) U226 cells over expressing Stim1 m-cherry show increased
trafficking to the plasma membrane following treatment with MTI-101 compared to control cells. Using
TIRF microscopy, images of individual cells (n = 7) at each time point were visualized, analyzed, and linked
through time. TIRF images were collected every 15 seconds over 30 minutes with the experimental group
receiving a single 2.5 μM treatment of MTI-101 at 30 seconds. Ft/F0 is the pixel intensity at the indicated
time as denoted on the X axis divided by the average pixel density prior to drug treatment. Mean intensity
data for STIM1 mCherry at each time point were extracted for comparisons. A representative cell from the
control group and treatment group is shown before treatment (0 min) and after treatment (5 and 10 min).
Shown is the mean and standard error of 7 cells for a representative experiment (p < 0.05, Two Way
ANOVA). The experiment was repeated 3 independent times and similar data was obtained [73].

Emmons and colleagues sought to determine the effect of combining MTI-101 and the standard of
care for the treatment of MM bortezomib in vitro and in vivo. In vitro, using the murine cell line
5TGM1, the combination of MTI-101 and bortezomib showed a combination indexes (CI) of less
than 1 in the 30 hours and up to 72 hours, indicating a synergy between both drugs. The
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combination index value is calculated using the CompuSyn software and the values are < 1, = 1,
or > 1. CI < 1 indicates synergism, CI = 1 indicates additive effect, and CI > 1 indicate antagonism
[100].

Additionally,

MTI-101,

bortezomib,

and

the

combination

were

tested

in

C57BL/KaLwRijHsd mice injected with 5TGM1 syngeneic MM cells, the outcomes of this study
showed improved anti-myeloma activity in the form of increased mean survival in the combination
treated group vs single agents or vehicle control. However, there was no significant reduction in
IgG2B levels in the combination compared to the single agent treated mice [73].
Clinically, the effect of MTI-101 was tested on MM patients’ specimens. The group compared the
effect of MTI-101 on newly diagnosed vs relapsed MM patients’ specimens by isolating the
CD138+ cells, as reported previously, MTI-101 was significantly more potent in relapsed patients
than in the newly diagnosed. Furthermore, to test whether Ca2+ overload plays a role in MTI-101induced cell death in patients’ specimen, cells were pre-treated with 2-APB, and similar to MM
cell lines, 2-APB significantly inhibited MTI-101 induced cell death, indicative of the role of Ca2+
overload in the mechanism of action. Lastly, combining MTI-101 with bortezomib showed
synergistic effect in patients’ specimens. These findings support further development for MTI-101
as prospective treatment for MM in combination with other treatments [73].
1.3.3. LOPAC1280™ library screen identified six drugs synergizing with MTI-101
The LOPAC1280™ is an annotated library formed of 1280 pharmacologically known and active
drugs. By screening the drugs with MTI-101 we aimed at identifying agents synergistic with MTI101. In the primary screen, we defined positive hits as drugs that in combination with MTI-101
would induce two folds increase in cell death. The primary screening hit rate was 5.94% (76 drugs
out the 1280 screened drugs) (figure 6 A). The secondary screen was for hit confirmation and was
defined as any hit that would cause two-fold increase in cell death in combination with MTI-101
compared to the hit or MTI- 101 alone. The secondary screen hit rate was 7.89% (6 drugs out of
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the 76 drugs from the primary screen hits) identified; Ebastine (histamine H1 receptor antagonist),
JNJ-40418677 (gamma-secretase modulator), SB-216763 (GSK3-β inhibitor), Tamoxifen citrate
(PKC inhibitor), R(+)-DIOA (potent [K+, Cl-]-cotransport inhibitor), and 7-Cyclopentyl-5- (4phenoxy) phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine (Selective inhibitor of GLS1) (figure 6
B and C ). The outcomes from this screening would allow us to further understand and determine
the mechanism of action of MTI-101, and to find possible FDA approved candidates that could
used down the road in clinical studies. This could attained by determination of the combination
index and the specificity of the combination to multiple myeloma cells, to correlate the
combination induced cell death with Ca2+ influx in in-vitro and in-vivo models, and to test the
combination in an in-vivo syngeneic mouse model (Figure 6 D).

A)

B)
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C)

D)
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Figure 6: LOPAC1280™ library screen identified six drugs synergizing with MTI-101: A)
Plot for the percent death in U266 cells following primary screen of the LOPAC1280™ library.
Cells were plated and treated with 10uM MTI-101 with 10uM of the each library drug for 3 hours.
Death was measured by DAPI. B) Secondary screen percent death of U266 cells treated with
combination of 76 hits and 10uM MTI-101 for 3 hours. Death measured by DAPI. C) The six hits
from the secondary screen along with the pathway they target. D) Workflow for determining the
best candidate to proceed with from the LOPAC1280™ library screen.
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2.1 Abstract
Calcium ions (Ca2+) play an important role as second messengers in regulating a plethora of
physiological and pathological processes, including the progression of cancer. Several selective
and non-selective Ca2+-permeable ion channels are implicated in mediating Ca2+ signaling in
cancer cells. In this review, we are focusing on TRPC1, a member of the TRP protein superfamily
and a potential modulator of store-operated Ca2+ entry (SOCE) pathways. While TRPC1 is
ubiquitously expressed in most tissues, its dysregulated activity may contribute to the hallmarks
of various types of cancers, including breast cancer, pancreatic cancer, glioblastoma multiforme,
lung cancer, hepatic cancer, multiple myeloma and thyroid cancer. A range of pharmacological
and genetic tools have been developed to address the functional role of TRPC1 in cancer.
Interestingly, the unique role of TRPC1 has elevated this channel as a promising target for
modulation both in terms of pharmacological inhibition leading to suppression of tumor growth
and metastasis as well as for agonistic strategies eliciting Ca2+overload and cell death in
aggressive metastatic tumor cells.

2.2 Introduction
Calcium is a ubiquitous second messenger that is known to regulate a myriad of physiological
cellular functions in normal cells [1]. Levels of intracellular free concentration of Ca2+ is tightly
regulated with strict spatial and temporal control to initiate, maintain, and terminate appropriate
signaling pathways and phenotypes. Changes in intracellular Ca2+ concentration include fast
processes that require milliseconds of intracellular Ca2+ spikes necessary for exocytosis and
muscle contraction to processes requiring minutes to hours of Ca2+ flux that affect cellular
proliferation, cell cycle control, migration, gene expression, and cell death [2,3]. Ion channels play
a fundamental role in defining regulatory signaling pathways in the progression of cancer. Further,
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numerous studies indicate that Ca2+-dependent signaling pathways are involved in augmenting
tumor proliferation, differentiation, migration, invasion, metastasis, and apoptosis, thus tumor
cells often exhibit increased expression of Ca2+ regulatory networks [2-4]. Morever, given the
importance of Ca2+ signaling, it is not surprising that cells tightly and precisely regulate proteins
handling Ca2+ signals, including receptors, channels, and transporters [5]. Regulation of Ca2+
homeostasis includes transient Ca2+ release from intracellular stores (ER/SR, mitochondria,
lysosomes) as well as more sustained influx of extracellular Ca2+ [6]. The store-operated Ca2+ entry
pathway (SOCE) is a major Ca2+ entry pathway in non-excitable cells and SOCE activity is known
to modulate insensitivity to antigrowth signals via multiple routes, as reviewed by Prevarskaya et
al [4]. There are numerous channels and transporters that regulate Ca2+ levels and deciphering the
role and interplay of individual members in facilitating tumor progression remains challenging.
There is a great deal of controversy surrounding the role of TRPC1; while some reports suggest it
is an ion channel, other reports suggest that TRPC1 alone is not sufficient to form an ion channel,
and functions as a modulator of other TRPC channels. Additionally, the expression of TRPC1 as
a prognostic marker in cancer appears to be context specific as TRPC1 expression has been
reported to be associated with poor clinical outcomes for certain types of cancers, while in other
indications it is reported to be associated with improved outcomes. This review will focus on the
role of TRPC1 expression as a determinant of SOCE and cancer progression.

The transient receptor potential (TRP) ion channels were first discovered in Drosophila
melanogasler by studying photo-transduction [7]. The TRP protein superfamily shares similarities
in structure to the parent Dorsophila TRP and were initially classified into 3 subfamilies TRPCanonical, TRP-Vanilloid, and TRP-Melastatin (TRPC, TRPV, and TRPM respectively) [8].
Later, the TRP superfamily was classified into 7 subfamilies; TRP-Classical/Canonical (TRPC),
35

TRP-Vanilliod (TRPV), TRP-Melastatin (TRPM), TRP-Ankyrin (TRPA), TRP-Polycystin
(TRPP), TRP-Mucolipin (TRPML). The non-mechanoreceptor potential C-TRP (TRPN), is
comprised of approximately 30 members [9]. Except for TRPM4 and TRPM5, which are Ca2+activated monovalent-selective cation channels [10,11], TRP family members are non-selective
channels that are permeable to Ca2+ to varying degrees [9]. TRP channels generally share structural
similarities that include six-transmembrane domains and the proteins typically assemble as
homotetrameric or in some cases heterotetrameric channels summarized by Strubing and
colleagues [12].

In addition to TRP channels, the SOCE mechanism of action is dependent on the depletion of
the endoplasmic reticulum (ER) Ca2+ stores through ryanodine receptors (RyR) or inositol 1,4,5trisphosphate receptors (IP3R) [13,14]. SOCE is regulated by agonist binding surface receptors,
including G-protein coupled receptors (GPCR) or receptor tyrosine-kinases (RTK), activating
phospholipase Cβ (PLCβ) via Gq/11 and PLCγ via RTK mediated signaling [2,6]. This results in
the enzymatic cleavage of plasma-membrane phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3
and diacylglycerol (DAG). The depletion of Ca2+ stores from the ER is sensed by the
transmembrane protein stromal interaction molecules (STIM1 and STIM2), as Ca2+ dissociates
from the EF domain of STIM1 and/or STIM2[15]. STIM molecules multimerize and translocate
to ER-PM junction to form puncta that co-assemble with any or all of three Calcium-ReleaseActivated Calcium (CRAC) channel subunits Orai1/2/3. This protein-protein interaction between
STIM and Orai results in the sustained opening of the highly Ca2+-selective CRAC channels that
allow for both cytosolic Ca2+ signaling and replenishing of ER stores [6]. Additionally, in some
cell types, STIM1 may intersect with Orai1 and members of TRPC subfamily by its reported

36

capability to directly interact with TRPC1, TRPC4, and TRPC5, and indirectly with TRPC3 and
TRPC6 (Figure 1A) [16-19].
The TRPC subfamily consists of seven members (TRPC1-7), and they are known to function
as non-selective cation channels, with permeability to Ca2+, Na+, and K+ [20]. The role of TRPC1
in SOCE activity has been discussed in a recent report by Dyrda and colleagues, where they
reported that TRPC1 activation is dependent on activation of the Icrac current activated by STIM1
and comprised of Orai1/2/3 [21]. However, activation of STIM1 doesn’t necessarily activate
TRPC1, as there are two proposed mechanisms for the store-operated channels activation. The
transmembrane protein STIM1 interacts with Orai1 activating the CRAC channels, with Ca2+
selective Icrac currents [22-25]. STIM1 interacts with TRPC1, forming STIM1/Orai1/TRPC1
complex and activating the SOC channels conducting a cation non-selective Isoc currents [25,26].
This experimental evidence supports a model in which, following the activation of the SOC
channels, the non-selective cation channels TRPC1, TRPC4, and TRPC5 form heterotetramers as
TRPC1/TRPC4, TRPC1/TRPC5, or TRPC1/TRPC4/TRPC5 become operative to facilitate further
Ca2+ entry (Figure 1B) [27-29]. TRPC1 has been under study in recent years as a Ca2+ channel in
the SOCE pathway, on the other hand, recent reports have suggested that TRPC1 when expressed
on it is own is not sufficient to form a channel. The role of TRPC1 has been studied extensively in
recent years to investigate its function as a calcium channel or a modulator for other TRPC
channels. Despite all data and studies into TRPC proteins, their mechanism of action remains
poorly understood. Some members of the TRPC subfamily are capable of forming channels when
expressed alone by forming homomers (TRPC4/TRPC4, and TRPC5/TRPC5) [30]. However,
Storch et al. reported that TRPC1 is incapable of forming Ca2+ permeable channel by itself but is
essential in forming heteromers with all other members of the TRPC subfamily [31]. Further, they
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reported a decrease in Ca2+ permeability in heteromeric complexes containing TRPC1, but the
effect of TRPC1 in Ca2+ entry and as a member of the SOCE pathway is tissue dependent.

The role of Ca2+ signaling through the SOCE pathway involving STIM1 and Orai1 has been
reported previously to affect prognosis of cervical, colorectal, breast, esophageal, multiple
myeloma, and lung cancers by affecting tumor growth, proliferation, metastasis, and survival
[3,32-34]. In this review we aim to address the role of TRPC1 as a member of the SOCE pathway
in promoting the advancement of the hallmarks of cancer and consider their potential as therapeutic
targets for developing novel cancer treatments.
2.3 Ca2+ signaling through SOCE modulates gene expression
Considering the numerous pathways that Ca2+ signaling modulates, including kinases,
phosphatases, proteases and metabolic enzymes, the role of Ca2+ signaling in progression of cancer
is likely multi-factorial. However, one attractive Ca2+ dependent candidate pathway is activation
of NFAT (reviewed by Putney[35]). Increased intracellular Ca2+ levels occurs via multiple
channels, but the increased oscillatory Ca2+ currents through emptying of intracellular stores, and
extracellular Ca2+ flux through the SOCE is the major contributor to Ca2+ regulated gene
expressions[36]. Ca2+ binding to its receptor calmodulin activates the phosphatase protein
calcineurin, which in turn dephosphorylates NFAT, leading to its translocation to the nucleus.
NFAT is a transcription factor known to regulate the expression of genes encoding cytokines and
receptors mandatory for T-cell survival. Multiple reports indicate that tumor cells have hijacked
the calcium dependent NFAT pathway to support cytokine dependent survival and homing. For
example, in diffuse large B-cell lymphoma (DLCBCL) Bucher et al., reported that NFAT activity
is chronically elevated in tumor cells; a finding that correlated with elevated Ca2+ levels. In
addition, inhibition of calcineurin with cyclosproin A or FK506 treatment reduced NFAT target
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genes including EGR2, IL10, NFKB1A and Jun and induced cell death in DLCBCL cell lines
[37]. Similarly, Urso et al., showed that NFATc3 is a critical determinant of proliferation and
migration of U251 glioblastoma cell lines[38]. The authors demonstrated that reducing the
expression of NFAT3c inhibited expression of TNF-alpha, GM-CSF, IL-2 and CXCR-3 when
U251 cells were treated with an ionophore. Finally, the authors demonstrated that a reduction of
NFAT3c inhibited growth of U251 cells in vivo. The role of NFAT in cancer progression has been
comprehensively reviewed by Mancini et al. where they reported that NFAT overexpression in
solid and hematological tumors plays a role in tumor survival, migration, and invasion[39](Figure
2).
2.4 Pharmacological and genetic tools used to probe role of TRPC in cancer
Numerous studies have addressed the role of TRPC1 as a Ca2+ channel using siRNA or shRNA
strategies to reduce the expression of TRPC1 [31,40-53]. The outcomes of silencing TRPC1 in
cancer cells are addressed below in detail in context to disease indication and contribution to
growth and metastasis. Other studies have employed various pharmacological tools to determine
the role of TRPC1 along with TRPC4 and TRPC5 as contributors to the SOCE pathways and Ca2+
entry. Some of these tools are inhibitors that suppress SOCE and cell proliferation, including 2APB [40,43,44,48,49,51-56], SKF96365 [31,51,53,55,57], and MRS1845 [51,53], whereas the
plant-derived sesquiterpenoid englerin A can be used as an agonist for TRPC4 and TRPC5 to
promote Ca2+ overload and cell death [41,58]. 2-APB was originally discovered as an IP3R
inhibitor, but has since been recognized as a fairly non-selective inhibitor of a large number TRP
channels that lack specificity for TRPC1 [59,60]. Similarly, SKF96365 was originally discovered
as an inhibitor of the receptor-mediated Ca2+ entry in platelets and endothelial cells. The compound
is also pleiotropic and found to inhibit SOCE via STIM1, to block various TRPC channels, as well
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as voltage-gated K+ and Ca2+ channels [61,62]. Finally, the dihydropyridine MRS1845 has been
reported as an inhibitor for the SOCE pathway in HL-60 leukemia cell line [63], but its potential
direct effects on TRPC1 have not yet been established in electrophysiological studies. Thus, these
inhibitors cannot be considered as specific reagents for TRPC1, and genetic confirmation is
required when using these pharmacological tools. Other more specific antagonists for TRPC1,
TRPC4, and TRPC5 have been discussed by Rubaiy, and include PICO 145, Clemizole, M084,
AC1903, Galangin and AM12.

These tools could facilitate future studies aimed at better

understanding the role of TRPC1 in cancer [64].
2.5 TRPC1 expression and correlation with Proliferation, EMT and migration
2.5.1. Pancreatic Cancer
Epithelial–mesenchymal transition (EMT) is a known modulator and a key step into tumor
invasion and metastasis. One of the key modulators of EMT is TGF-β, which has been reported
previously to induce EMT in mammary epithelial cells [65]. The role of TRPC1 as a Ca2+ channel
in pancreatic cancer cell proliferation and its development was proposed as being a downstream
effector of TGFβ signaling [52,56]. In SMAD4-null pancreatic cancer cells, TGFβ is reported to
induce a cytosolic Ca2+ increase, leading to the activation of the Ca2+-dependent protein kinase Cα (PKCα) and its translocation to the plasma membrane. Further, TGFβ activated PKCα-dependent
cellular motility and migration, by inhibiting the tumor suppressor PTEN [56]. Later, TRPC1 4
and 6 levels were shown to be high in pancreatic cancer cells, indicating their function as TGFβ
mediators for Ca2+ entry [52]. Pharmacologically inhibiting SOCE pathways using 2-APB and
La3+ abrogated the TGFβ-dependent increase in cytosolic Ca2+ levels. Blocking PKCα by the
selective PKCα inhibitor Gö-6976 also inhibited TGFβ induced Ca2+ flux [52]. Further, siRNA
knockdown of TRPC1 or treatment with 2-APB significantly inhibited pancreatic cancer cell
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motility induced by TGFβ, although interestingly, siRNA knockdown of TRPC4 and 6 had no
effect on TGFβ-induced pancreatic cell motility [52].
2.5.2. Breast Cancer Epithelial-Mesenchymal Transition and Proliferation
It has previously been reported that epithelial-mesenchymal transition (EMT) is associated
with upregulation of SOCE via increased levels of STIM1 and Orai1 in MCF7 and MDA-MB-231
cell lines, promoting invasion and proliferation of breast cancer cells [54]. However, the role of
the SOCE pathway in EMT may be dependent on the stimulus inducing the transition and/or cell
context specific.

For example, in MDA-MB-468 cell lines undergoing EGF-induced EMT

correlates with a reduction of SOCE activity, and the reduction in Ca2+ flux was associated with
Orai1 downregulation, while TRPC1 expression was not altered [50]. Interestingly, hypoxiainduced EMT increased the expression of TRPC1 in MDA-MB-468, MDA-MB-231, and
HCC1569 cell lines, an effect that requiredHIF1α expression, indicating that TRPC1 is a HIF1α
target . Reducing TRPC1 expression inhibited hypoxia-induced increased Snail, Vimentin and
Twist expression. Reducing the expression of TRPC1 in hypoxia resulted in decreased basal Ca2+
levels but increased SOCE activity was noted by depleting intracellular stores using the
Sarco/Endoplasmic Reticulum Ca2+ ATPase (SERCA) inhibitor cyclopiazonic acid [42].
Reducing the expression of TRPC1 in MDA-MB-468 cells decreased the proliferation rate and
was associated with reduction of cells in the S-phase, while Orai1 had no effect [50].
MCF7 breast cancer cells proliferate in response to activation of the Ca2+-sensing receptor
(CaR) by extracellular Ca2+ or its agonist spermine [66]. El Hiani and colleagues reported that
Ca2+-mediated CaR activation in MCF7 cells results in activation of PLC and PKC [55].They
further reported that proliferation is dependent on activation of ERK1/2 which was shown to be
activated downstream of PLC and PKC. Reducing the expression of TRPC1 attenuated ERK1/2
phosphorylation mediated by CaR activation, which is necessary for CaR-induced cell
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proliferation of MCF7 cells. In addition, reducing TRPC1 expression inhibited MCF7 proliferation
by halting the cell cycle progression at the G1 phase [45]. Cell cycle progression was dependent
on TRPC1 mediating the activity of Ca2+-activated K+ channels (KCa3.1) [45,55]. Interestingly, a
feed-forward loop was described where TRPC1 expression was dependent on activation of EGFR
and ERK activity in MCF7 cells [67]. In human breast ductal adenocarcinoma primary patient
samples, TRPC1, TRPC6, TRPM7, and TRPM8 were reported to be overexpressed in cancer cells
compared to normal adjacent tissue. Importantly, increased TRPC1 expression correlated with
expression and increased proliferative and invasive capacity of small grade I breast cancer tumors
[68]. Taken together, these data suggest that TRPC1 expression may play a role in facilitating
EMT and proliferation and further studies are required to carefully delineate the mechanism
underpinning the role of TRPC1 in mediating EMT and proliferation in breast cancer.

2.5.3. Glioblastoma
In D54MG cells, a model for malignant gliomas or glioblastoma multiforme (GBM), the
pharmacological inhibition of SOCE with 2-APB, SKF96365, and MRS1845 significantly reduced
both Ca2+ influx and proliferation as well as the formation of multinucleated cells, a characteristic
of GBM [53]. To define the role of TRPC1 as a Ca2+ channel involved in SOCE, its function was
blocked using a polyclonal-TRPC1 antibody, which reduced the Ca2+ entry by 25%, whereas no
effect was seen with TRPC5 inhibition [53]. Similarly, Ca2+ entry was significantly decreased
following the reduction of TRPC1 expression using shRNA [53]. The knockdown of TRPC1 also
significantly reduced proliferation and resulted in enlarged multinucleated cells. Moreover,
TRPC1 expression levels were reportedly down-regulated in patients with giant cell glioblastoma
[53].
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It has been reported that lipid rafts microdomains (LRD) and plasma membrane caveolin-1
are critical for TRPC1 insertion into the plasma membrane and its activity as Ca2+ channel, as
TRPC channels contain a caveolin-1 binding domain [69-71]. Indeed, TRPC1 was implicated in
chemotaxis and directional migration of D54MG cells towards epidermal growth factor (EGF) by
co-localizing with caveolin-1 and lipid rafts in the cells’ leading edge, which was abrogated with
inducible TRPC1 shRNA knockdown [51]. Consistent with the importance of Ca2+ signaling, the
use of SOCE inhibitors MRS1845 and SKF96365 disrupted glioma migration [51]. Evidence that
TRPC1 expression is essential for growth in vivo was assessed by injecting nude mice glioma cells
ectopically expressing doxycycline-inducible shRNA targeting TRPC1. Mice with inducible
knockdown of TRPC1 had a shallow, significantly smaller tumor size compared to wild-type
TRPC1 expression, However, propensity for metastasis was not evaluated in these mice [53].
2.5.4. Lung cancer
Lung cancer is the leading cause of death from cancer in men and women and thus clinical
data continue to indicate the need for new treatment strategies to improve patient outcomes [72].
Levels of TRPC protein expression and their relation to tumor prognosis have been reported
previously and identified as a potential target for treatment. TRPC1, TRPC3, TRPC4, and TRPC6
levels have been found to be highly expressed in patient specimens compared to other TRPC
channels [49,73]. Moreover, overexpressing TRPC1 and TRPC6 in A549 NSCLC cell line was
sufficient to increase proliferation, while blocking TRPC channels by the IP3 receptor inhibitor
and SOCE modulator 2-APB or the specific TRPC1, TRPC3/TRPC6 antibodies T1E3 and
T3667E3 inhibited A549 cells proliferation [49].
As mentioned earlier, TRPC1 levels in breast cancer were dependent on HIF-1α following
hypoxia-induced EMT. Wang et al. reported similar results in lung cancer by exposing A549 cells
to high nicotine levels, which in turn resulted in increased HIF-1α levels (as shown previously by
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Guo et al. [74]), leading to the upregulation of SOCE components, namely Orai1, TRPC1, and
TRPC6 [75]. Further, the nicotine exposure was associated with increased basal intracellular Ca2+
levels in A549 cells related to constitutive SOCE activity. Downregulating HIF-1α was associated
with low expression of Orai1, TRPC1, and TRPC6, and resulted in decreased proliferation of A549
cells. Silencing TRPC1 decreased hypoxia-induced autophagy [75]. Autophagy is known to
promote survival in hypoxic environments [76] albeit no data was reported on survival with respect
to exposure to hypoxia and TRPC1 expression. More recently, STIM1 and TRPC1 were shown to
mediate cisplatin cytotoxicity in NSCLC by facilitating DNA Damage Response (DDR) and
reactive-oxygen species (ROS) production leading to apoptosis. While these effects were
discovered mostly by silencing STIM1, and thus do not rule out Orai1 or other SOCE components,
the overall effect was mainly mediated by inhibition of Ca2+ influx through the SOCE pathway
[40].
2.5.5. Colon Cancer
In colon cancer, the role of SOCE members, mainly TRPC1 and Orai1 has been discussed
thoroughly by Villalobos et al [77]. Basal Ca2+ levels have been shown to be higher in HT29 colon
carcinoma cell lines with higher increase in cytosolic Ca2+ in response to agonists like ATP and
carbachol compared to the normal human mucosa cell line NCM460 [48]. Although TRPC1
mRNA levels were similar to other SOCE members in HT29 cells, there was an increase in protein
expression levels compared to others, and TRPC1 silencing was associated with decreased storeoperated (Isoc) currents. As previously mentioned, TRPC1 facilitates the migration of GBM cells
towards EGF. Guéguinou et al. investigated the mechanism by which TRPC1 contributes to colon
cancer cell migration. They demonstrate that reducing the expression of TRPC1 inhibits migration
of HCT-116 colon cancer cell line by disrupting the complex formation of Ca2+-activated K+
channels (SK3), Orai1, and TRPC1 in the lipid rafts [44]. Further, colon cancer cell migration was
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shown to be dependent on EGFR activation, leading to downstream activation of the PI3K/Akt
pathway. This promotes the phosphorylation activation of STIM1 and SOCE, leading to the
translocation of TRPC1 and Orai1 in the lipid rafts to form a complex with SK3, which allows a
loop formation of further Akt activation and TRPC1/ORA1/SK3-dependent migration. Taken
together, TRPC1 expression appears to have a role in the migration of multiple cancer types and
more studies are required to determine whether inhibition of this pathway will block metastasis of
primary tumors.
2.6 Activation of SOCE pathway for inducing cell death in cancer
Cancer requires robust Ca2+ signaling to support proliferation, invasion and metastasis,
whereas excessive Ca2+ levels lead to apoptosis and cell death, Both the suppression and
enhancement of the SOCE pathways may be exploited for treatment of cancer. In Triple negative
breast cancer (TNBC), Grant et al. reported that TRPC1 and TRPC4 were overexpressed in some
TNBC cell lines. For example, the Hs578T TNBC cell line showed high expression levels of
TRPC1 and TRPC4 compared to the MD-MB-231 TNBC cell line, and the BT-549 TNBC cell
line had high levels of TRPC4 when compared to MD-MB-231 cell line [41]. The higher TRPC
expression levels in these cancer cells may render these cells more vulnerable to therapeutic
strategies aimed at eliciting Ca2+ overload and cell death through channel agonists rather than
pharmacological inhibition to reverse hallmarks of cancer.
Support of Ca2+ overload being a vulnerability for cancer is that TNBC cell lines with
increased TRPC4 and TRPC5 showed increased sensitivity to the TRPC4 and TRPC5 activator
englerin A (EA) compared to cell lines with reduced expression [41]. Interestingly, the expression
of TRPC4 and TRPC5 alone did not yield sensitivity to EA-induced and Ca2+-dependent cell death,
indicating the importance of the heteromeric formation of TRPC members. Although TRPC1
levels in BT-549 cells were comparable to the EA-resistant cell line HCC1806, BT-549 cells
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showed increased sensitivity to EA-induced Ca2+ entry and cell death when compared to Hs578T,
when TRPC4 alone is predominantly and highly expressed. A possible explanation for this is the
shift of the heteromeric TRPC1/TRPC4 channel towards more Na+ flux [31]. In renal cell
carcinoma (RCC), A498 RCC cell lines responded to englerin A by elevation of intracellular Ca2+
levels and followed by cell death The Ca2+ entry was due to activation of TRPC4 channels as was
demonstrated by patch-clamp studies. Further, while the expression of only TRPC1 did not
contribute as a Ca2+ channel to the englerin A-induced Ca2+ overload and cell death, the coexpression of TRPC1 and TRPC4 and their heteromeric formation reproduced the same Ca2+ entry
currents in HEK293 cells [58].
These findings corroborate the importance of TRPC1 expression for the overall functionality
of the SOCE pathway. Our laboratory has shown that the novel cyclic peptide referred to as MTI101 induces a robust and sustained increase in intracellular Ca2+ levels in multiple myeloma cells
lines [78,79]. Emergence of resistance to chronic exposure of increasing concentrations of MTI101 in the multiple myeloma H929 cell line correlated with decreased expression of the IP3
receptor, SERCA pump, PLCβ, TRPC1 and TRPM7. Treatment with the pharmacological
inhibitor 2-ABP attenuated MTI-101-induced Ca2+ influx, a finding that correlated with decreased
cell death. U266 and MM1.s myeloma cells with reduced expression of TRPC1 using shRNA
strategies showed a reduction in MTI-101 induced cell death [78]. Further studies are required to
determine the role of TRPC1 in mediating MTI-101 induced Ca2+ entry and whether MTI-101induced activity is dependent on activation of TRPC1 heteromers and regulation of the SOCE
pathway, thereby allowing for sustained Ca2+ influx and leading to caspase-independent cell death
[79]. Interestingly, MTI-101 was found to be more active in primary specimens obtained from
myeloma patients relapsing on standard of care agents.

Together, these data suggest that

stimulating Ca2+ overload maybe a unique vulnerability to cancer cells, as experimental evidence
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indicates that cancer cells remodel Ca2+ handling pathways to favor Ca2+ influx required to
facilitate the hallmarks of cancer.
2.7 Clinical outcomes
As outlined above, several TRPC members have been studied and implicated in the promotion
of cancer through tumor cell proliferation, migration, invasion, and survival, as observed in lung
cancer, malignant glioma, neuroblastoma, renal cell carcinoma, hepatoma, thyroid cancer, colon
cancer, and breast cancer [43-47,57,80,81]. With respect to TRPC1, the screening of patient
specimens as well as the mining of large data sets have yielded several clinically relevant insights
in patients with tumors expressing TRPC1. Faouzi et al. reported TRPC1 to be expressed in all
examined 17 data sets of breast cancer specimens, with no specific clinical significance [45]. Azimi
et al. reported the TRPC1 expression levels in a data set from the University of North Carolina of
855 breast cancer patients, classified and reported based on the 50-signature genes subtype
classification known as PAM50 [42,82]. The claudin-low breast cancer subtype exhibited the
highest TRPC1 expression levels compared to other subtypes. Further, in TNBC, the mesenchymal
subtype showed the highest expression level of TRPC1, and the basal subtype with lymph-node
metastasis showed worsened prognoses associated with high TRPC1 expression levels [42]. In
lung cancer, SOCE components including STIM1, Orai1 and TRPC channels have been examined
in a dataset of more than 2,000 cases. While TRPC1 had no effect on the risk of lung cancer, two
variants of TRPC4 namely (rs9547991 and rs978156), and one variant of TRPC7 (rs11748198)
were associated with increased risk of lung cancer compared to control subjects [57]. TRPC1
plasma membrane levels have been reported to be low when in inactive status, being located in
close proximity to the plasma membrane. Transfer to the plasma membrane is dependent on Ca2+
signals generated by STIM1-Orai1 activation [83]. Thus, membrane localization may be an
important factor linking SOCE and TRPC1 functions, even if expression levels may not change.
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Considering the function of TRPC1, it is feasible that quantification of membrane staining of
TRPC1 may lead to increased sensitivity as a prognostic indicator in cancer.
2.8 Summary
Experimental evidence indicates that although TRPC1 may not represent a driver of cancer,
the expression of TRPC1 contributes to the hallmarks of cancer. To further the understanding of
TRPC1 functionality in vivo, various TRPC knockout mice were created and used in different
settings. A Hepta-KO cell line was created by combining cell lines with 5 TRPC knockout alleles,
with TRPC2 KO, along with TRPC4 knockout, formulating a null cell line devoid of all 7 TRPC
members. Surprisingly, the Hepta-KO model has a functional SOCE system regardless of TRPC
expression [84]. These data suggest that the SOCE can function independent of TRPC expression.
However, it is feasible that TRPC1 function requires activation such as hypoxia or a
reprogramming switch to EMT in order to modify the SOCE pathway. It is also possible that
TRPC1 acts as a modulator in only a subset of cell types and/or under specific (patho)physiological circumstances. Thus more studies are required to inform the role of TRPC1 in the
context of cancer in genetically engineered mouse models. Finally, the development of more
specific pharmacological tools for inhibiting or activating TRPC1 function are needed to fully
validate TRPC1 as a potential target for the treatment of cancer.
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2.11 Figure Legends
Figure 1. The Store-Operated Ca2+ Entry pathway (SOCE): A) SOCE is regulated by
agonist binding to G-protein coupled receptors (GPCR) or receptor tyrosine-kinases (RTK),
activating phospholipase Cβ (PLCβ) via Gq/11 and PLCγ via RTK mediated signaling,
resulting in the production of IP3 and DAG from the cleavage of plasma-membrane PIP2. IP3
depletes Ca2+ stores from the ER through the IP3R which is sensed by STIM1. B) STIM
molecules multimerize forming puncta and translocate to ER-PM junction co-assembling with
the CRAC channel subunits Orai1 activating the Ca2+ selective Icrac currents. Further, STIM1
forms STIM1/Orai1/TRPC1 complex activating cation non-selective Isoc currents.
Figure 2. Ca2+ entry through SOCE activates NFAT activation: Ca2+ entry through Icrac
channel binds calmodulin, leading to the activation of the phosphatase protein calcineurin,
activating the transcription factor NFAT. Active NFAT is translocated to the nucleus
regulating the expression of genes promoting proliferation, migration, and survival.
Table 1. Role of TRPC expression or activity in augmenting proliferation and metastasis in
cancer.
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Table 1:
Cancer Type
Pancreatic

Breast

Cell Type
BxPc3 (Human
ductal
adenocarcinoma)
MDA-MB-468
(EGF-mediated
EMT cells) (Human
breast
adenocarcinoma)

Native
TRPC
expression
↑ TRPC1
Comparable
to MDAMB-231 EMT

Lung

TRPC1 / siRNA

↑ TRPC1 &
TRPC3

TRPC1 / siRNA

MCF7
(adenocarcinoma)

↑TRPC1

TRPC1 / siRNA

↑ TRPC1

-

↑ TRPC1
↑ TRPC6

-

D54MG (GMB Cell
line)

-

TRPC1 / 2-APB,
SKF96365,
MRS1845,
polyclonal TRPC1 ab
, and shRNA

Primary patient cells
(NSCLC)

↑ TRPC1,
3,4,6

-

A549 (NSCLC cell
line)
A549 (hypoxiamediated EMT by
Nicotine treatment)

Colon

SOC / 2-APB
TRPC1 / siRNA

•
•

MDA-MB-468
Hypoxia-mediated
EMT cells)

Primary patient
TNBC cells
(mesenchymal
subtype)
Primary human
breast ductal
adenocarcinoma
Glioblastoma
Multiforme

Silenced proteins /
Tools used

↑ TRPC1
↑ TRPC6
↑TRPC1
↑TRPC6,
and ↑Orai1

HT29 (human colon
carcinoma)

↑ TRPC1
(protein)

HCT116

-

( - ) INDICATES NO AVAILABLE DATA

SOC / 2-APB
TRPC1,
TRPC3-TRPC6
/ T1E3, and
T3667E3 ab

•
•

↓TRPC1 / siRNA
HIF-1α

•
•

SOC / 2-APB
TRPC1 / siRNA

TRPC / siRNA
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Native expression
effect / Silencing effect
Motility / ↓ Motility
(TGFβ-dependent
motility)
-

/ ↓ Cell
proliferation (↓Sphase)

-

/ ↑ Ca2+ influx in
SOCE & ↓
autophagy
marker LC3BIII
Proliferation / ↓
Proliferation
(↓G1-phase)

Worsened prognosis / ↑ proliferation &
invasion / Proliferation, migration
/ ↓ Ca2+ influx in
SOCE, ↓ proliferation
High expression with
well differentiated
tumor
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e
[52]

[50]

[42]

[45, 55]

[42]

[68]

[51, 53]

[49, 73]
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Proliferation

[49]

↑ SOCE activity / ↓
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[75]
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Invasion
Migration / ↓ Migration

[48]
[44]
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3.1 Abstract
Multiple Myeloma (MM) is a currently incurable hematologic cancer. Patients that initially
respond to therapeutic intervention eventually relapse with drug resistant disease. Thus, novel
treatment strategies are critically needed to improve patient outcomes. Our group has developed a
novel cyclic peptide referred to as MTI-101 for the treatment of MM. We previously reported that
acquired resistance to HYD-1, the linear form of MTI-101, correlated with repression of genes
involved in store operated Ca2+ entry (SOCE): PLCβ, SERCA, ITPR3, and TRPC1 expression. In
this study, we sought to determine the role of TRPC1 heteromers in mediating MTI-101 induced
cationic flux. Our data indicate that consistent with activation of TRPC heteromers MTI-101
treatment induced Ca2+ and Na+ influx. However, replacing extracellular Na+ with NMDG did
not reduce MTI-101-induced cell death. In contrast, decreasing extracellular Ca2+ reduced both
MTI-101-induced Ca2+ influx as well as cell death. The causative role of TRPC heteromers was
established by suppressing STIM1, TRPC1, TRPC4 or TRPC5 function both pharmacologically
and by siRNA, resulting in a reduction in MTI-101-induced Ca2+ influx. Mechanistically MTI-101
treatment induces trafficking of TRPC1 to the membrane and co-immunoprecipitation studies
indicate that MTI-101 treatment induces a TRPC1-STIM1 complex. Moreover, treatment with
calpeptin inhibited MTI-101-induced Ca2+ influx and cell death indicating a role of calpain in the
mechanism of MTI-101-induced cytotoxicity. Finally, components of the SOCE pathway were
found to be poor prognostic in-dicators among MM patients, suggesting that this pathway is
attractive for the treatment of MM.
Keywords: Multiple Myeloma, SOCE, Calcium, TRPC
3.2 Introduction
Multiple myeloma (MM) is a malignancy arising from neoplastic proliferation of plasma cells in
the bone marrow. MM is the second-most common form of blood cancer accounting for 17% of
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hematological malignancies, with an estimated 34,920 cases in the United States in 2021, and
12,410 deaths [1-3]. Multiple new therapies emerged recently for the treatment of MM, yet
unfortunately MM patients continue to progress toward a refractory disease and thus MM remains
incurable with current treatment strategies and novel treatment strategies are required to improve
patient outcomes.
Cytosolic Ca2+ homeostasis is essential for multiple physiological functions including metabolism,
protein phosphorylation, cell proliferation, gene transcription, homing and contractility, and thus
the coordinated regulation of Ca2+ channels, pumps, transporters, and exchangers is essential for
survival [4,5]. Cytoplasmic intracellular Ca2+ concentration ranges between 10-100 nM, while
extracellular Ca2+ concentration is 1.2 mM [6]. Multiple Ca2+ channels, pumps, transporters, and
exchangers are located on the plasma membrane and on cytoplasmic organelles membranes and
function to maintain the Ca2+ gradient across the plasma membrane and equilibrate Ca2+
intracellularly [5]. Ca2+ depletion of intracellular stores triggers the influx of extracellular Ca2+
through Ca2+-permeable channels in the plasma membrane, a mechanism termed Store-Operated
Ca2+-entry (SOCE). This pathway is considered the major Ca2+ entry pathway in many nonexcitable cells.
The core of the SOCE pathway is the Ca2+ Release-Activated Ca2+ (CRAC) channels located in
the plasma membrane. These CRAC channels can form homo- or heteromeric channels encoded
by three genes Orai1-3, of which Orai1 is most predominantly expressed. When ER Ca2+ stores
become depleted, ER-bound Ca2+-sensing partners Stromal interaction molecules (STIM1 and
STIM2) multimerize and translocate to the ER-PM junction. STIM1 interacts with Orai subunits
forming a Ca2+-conducting channel complex that functions to elevate cytoplasmic Ca2+ and
replenish ER Ca2+ stores [7,8]. In some cells, Ca2+ entry can be modulated by TRPC channels that
also interact with STIM [9]. The SOCE pathway functions to increase cytoplasmic Ca2+ following
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signal transduction of several pathways: i) agonist-targeted G protein-coupled receptors (GPCR);
ii) ligand-target receptor tyrosine-kinases (RTK), and iii) engagement of lymphocyte antigen
receptors. Physiological activation of these receptors leads to the activation of PLC and subsequent
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2), generating inositol 1,4,5trisphosphate (IP3), which in turn directly activates the IP3 receptor (IP3R), mediating Ca2+ release
from the ER lumen and active store depletion [10]. The sarcoplasmic/endoplasmic reticulum Ca2+
ATPase (SERCA) maintains low cytoplasmic Ca2+ levels by pumping Ca2+ into the SR and ER
lumens. Pharmacological inhibition of the SERCA by thapsigargin (Tg) or cyclopiazonic acid
(CPA) prevents ER refilling and enables leak pathways to passively deplete stored Ca2+ leading to
the activation of the SOCE pathway [11].
STIM1/Orai1 co-localization generates inwardly rectifying and highly selective Ca2+ currents
known as CRAC currents (ICRAC) [12].ICRAC can be triggered by depleting ER Ca2+ stores with
SERCA pump inhibitors (Tg, and CPA), chelating cytoplasmic Ca2+, or by applying IP3 to the
internal side of a cell during a patch-clamp recording [13-15]. On the other hand, STIM1/TRPC
co-localization may generate a non-selective, cationic channel that allows entry of Ca2+ and Na+,
and has been referred to as the ISOC current [12,16]. Activation of GPCR or RTKs can signal
laterally in the membrane and augment signals in a context specific manner[17]. For example,
integrin signaling has been shown to augment both growth factor receptor signaling and GPCR
signaling. However, integrin signaling also changes multiple downstream pathways including
MAPK, AKT, FAK and formation of focal adhesion leading to cytoskeletal rearrangements [17].
Thus ligand stimulated activation of ICRAC in the context of interactions with the tumor
microenvironment is likely more complex when compared to isolation of the ICRAC signaling
cascade; via specific pharmacological tools including cell permeable IP3 and blocking of the
SERCA pump [18-20]. TRPC1 can form heteromeric channel assembles with TRPC4 and TRPC5
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subunits, contributing to Ca2+ entry and the activation of these channels remains poorly understood
[21-23].
We previously reviewed the role of TRPC1 as a function of tumor progression and the hallmarks
of cancer [24]. Multiple studies have reported the role of TRPC1 in cancer proliferation, migration,
and invasion in pancreatic, lung, breast, colorectal, and multiple myeloma cancers [25-28].
However, the mechanism by which TRPC channels and the SOCE pathway contribute to these
pathophysiological outcomes is not fully understood. Furthermore, there is a pharmacological
opportunity to consider this pathway as a strategy for novel cancer treatment. [21]. HYD-1 is a
D-amino acid linear peptide that was originally discovered to inhibit tumor cell adhesion to
immobilized extracellular matrix proteins [29]. We later reported that HYD-1 and the more potent
cyclic peptide MTI-101 induced necrotic cell death through depolarization of the mitochondrial
membrane potential, reactive oxygen species (ROS) production, and ATP depletion[30,31]. To
further understand the mechanism and determinants of resistance we developed a HYD-1-acquired
drug resistant MM cell line. A comparative gene expression profiling between the parental drug
sensitive and resistant variant revealed changes in genes encoding for multiple components of Ca2+
entry pathways including TRPC1, TRPM7, ATP2A3, PLCB, and ITPR3 [32]. The cell line was
selected for resistance to the linear peptide HYD-1, but the resistant variant was cross-resistant to
MTI-101 induced cell death. Finally, we showed that HYD-1 and MTI-101 induced increased
Ca2+ influx, and that relapsed multiple myeloma patients' specimens were more sensitive to
treatment with MTI-101 when compared to specimens obtained from newly diagnosed patients
[32]. The non-specific SOCE inhibitor 2-APB attenuated MTI-101-induced cell death in MM cell
lines and in patients’ specimens. Translationally, MTI-101 synergized with MM standard of care
treatment bortezomib in C57BL/KaLwRijHsd mice, where the combination treatment significantly
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increased survival [32]. In this study, we sought to further characterize the role of STIM1-TRPC
heteromers in contributing to MTI-101 induced cell death.
3.3 Materials and Methods
3.3.1. Cells and Reagents
U266 (ATCC Cat# TIB-196) and MM.1s (ATCC Cat# CRL-2974) multiple myeloma (MM) cells,
and HS-5 (ATCC Cat# CRL-11882) bone marrow stroma cells were purchased from American
Type Culture Collection (Manassas, VA), they were maintained in RPMI-1640 medium with Lglutamine (Gibco; Life Technologies) with 10% Fetal Bovine Serum (FBS) and 1%
penicillin/streptomycin. The cell lines were validated by short tandem repeat (STR) and they were
also tested for mycoplasma every six months. MTI-101 was synthesized by Bachem (San Diego,
CA). Thapsigargin (Tg) (Millipore Sigma) was used to inhibit the SERCA pumps, calpeptin
(Selleckchem) was used to inhibit calpain I/II, SKF96365 (Selleckchem), or ML204 (Selleckchem)
were used to inhibit TRPC channels, and GSK7975A (Millipore Sigma) was used to inhibit CRAC
channels.
3.3.2. Ca2+ Imaging and Cell Death Assay
Intracellular Ca2+ levels were measured in U266, MM.1s, and HS-5 cell lines using the Fluo-4AM calcium indicator dye. Briefly, cells were seeded at 7.5x105 cells per ml in their respective
media with 2.5 µM Ca2+ sensitive dye Fluo-4-AM (Life Technologies) for 45 minutes in 37 ºC in
5% tissue culture incubator, cells were washed and resuspended in media to allow to deesterification for 30 minutes. Cells were then resuspended in either Live Cell Imaging Solution
(molecular probes; Life Technologies), 50 mM KCl physiological saline solution (PSS) or 5 µM
CaCl2 PSS, N-methyl-d-glucamine (NMDG)-Ringer, or Na+ Ringer solutions. All solutions
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contained 1 µg/ml DAPI (Thermo Scientific) as an indicator of cell death. 50 mM PSS contained
(in mM): NaCl 93, KCl 50, CaCl2 2.5, MgCl2 1.2, glucose 7.7, HEPES 10, and PH at 7.2 by
NaOH, while 5 µM CaCl2 PSS contained (in mM): NaCl 140, KCl 3, and CaCl2 at 5 µM, NMDGRinger contained (in mM): NMDG 140, KCl 3, CaCl2 2,5, MgCl2 1.2, glucose 7.7, HEPES 10,
and PH at 7.2 by NaOH, Na+ Ringer contained (in mM): NaCl 140, KCl 3, CaCl2 2,5, MgCl2 1.2,
glucose 7.7, HEPES 10, and PH at 7.2 by NaOH. Cells were plated in black-side, clear bottom
384-well plates (Nunc), pre-coated with Cell-Tak (Corning) at 3 µg/cm2 in NaHCO3 per
manufacturer’s instructions. Ca2+ fluorescence by Fluo-4-AM was captured using excitation and
emission of 488, and 510, respectively. Cell death was measured by DAPI using excitation and
emission of 377, 447 respectively. Images were captured using the BIOTEK Cytation 5 imager.
Ca2+ imaging was performed every 30 seconds for 60 minutes. Captured images were analyzed
using Nikon NIS Elements AR software. Images of individual cells (n=50) were traced over time
and analyzed for their Fluo-4-AM and DAPI fluorescence. Data presented in graphs show single
cell Fluo-4-AM signal as a representative for 50 cells, while the mean of 50 cells was used to
determine the peak area under the curve (AUC), and the maximum peak intensity. To correlate
the level of intracellular Ca2+ with induction of death, experiments were done as mentioned above,
but with imaging every 5 minutes under the same conditions. Data analysis were done using the
BioTek GEN 5.0.3 software, where the threshold of DAPI fluorescence was set to capture only
dead cells, and all data in the field of the image were analyzed and normalized to the total cell
count in the same field of view.
3.3.3. DiBAC4(3) Membrane Potential Measurement
Cells were plated in a 384-well plate pre-treated with Cell-Tak (Corning) at 25,000 cells/well.
Cells were then loaded with 250nM DiBAC4(3) (Bis-(1,3-Dibutylbarbituric Acid) Trimethine
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Oxonol) (Thermo Fisher) for 20 minutes in 37 ºC in 5% tissue culture incubator. DiBAC4(3) was
added to cells in Live Cell Imaging Solution and 50 mM KCl physiological saline solution (PSS)
(as mentioned above). The indicator was removed, and cells were loaded with their respective
buffer. Membrane potential fluorescence indicated by DiBAC4(3) was captured using excitation
and emission of 488, and 510, respectively, using the BIOTEK Cytation 5 imager. Fluorescence
was captured every 30 seconds and analyzed as mentioned previously.
3.3.4. Quantitative Real-Time PCR (qRT-PCR)
qRT-PCR was performed as previously described [32]. Briefly, 5 µg of total RNA was reverse
transcribed using SuperScript III First-Strand Synthesis (Thermofisher) following Total RNA
extraction by Trizol (Invitrogen). Real-time PCR was performed on the ABI Prism 7500 Fast
instrument (Applied Biosystems) using Sybr Green I Mastermix (Thermofisher). Samples were
tested in triplicates, three independent times and GAPDH was used as endogenous control product.
Primer sequences were as follows: GAPDH forward 5’-GCATCTTCTTTTGCGTCGCC-3’ and
reverse

5’-

GCGCCCAATACGACCAAATC-3’,

TRPC1

forward

5’-

GAGCAGAGGATGACGTGAGG-3’ and reverse 5’- CCCAGGAAGAGGACGAGAGA-3’,
TRPC4

forward

5’-AACAATAGGGAGGCGAGCTG-3’

and

reverse

5’-

CGGTCAGGOCCTTCTTCAGTT-3’, and TRPC5 forward 5’-GCCACACCTTGIAGGACCTC3’ and reverse 5’- CTGCCCACGTACACTAAGCA-3’.
3.3.5. Small Interfering RNA Transfection
The transfection of U266 and MM.1s cell lines were done using the Lonza 4D-Nucleofector system
(Lonza, Switzerland). Briefly, 2x106 cells were resuspended in the Lonza SF-kit (Lonza, V4XC)
with 10 µl of 20 µM stock of the respective small interfering RNA (siRNA). siRNA concentration
was determined as previously reported [31]. Cells along with siTRPC4 (Dharmacon, ON72

TARGETplus SMARTpool), siTRPC5 (Santa Cruz Biotechnology, sc-42670), siTRPC1 (Santa
Cruz Biotechnology, sc-42664) and siControl (Dharmacon ON-TARGETplus Non-targeting Pool)
were added along with buffer to the cuvette and electroporated at the recommended settings by
LONZA. Cells were incubated in the buffer for 10 minutes at 37 º C, cells were then transferred to
a T25 flask in 5 ml of media and incubated for 96 hours.
3.3.6. Fura-2AM Based Ca2+ Imaging
Cells were loaded with 4.0 μM Fura‐2-AM, then plated in a 96‐well plate at a density of 60 000
cells/well and fluorescence measurements were made on a Hamamatsu FDSS7000EX kinetic plate
reader. Fura-2 was excited at 340 and 380 nm, and the ratio of the respective emission fluorescence
at 510 nm was determined. Sampling interval was 3 s. The change in fluorescence ratios from
baseline were reported. Bath solutions contained (in mm): NaCl 140, KCl 5.4, CaCl2 2, MgCl2 0.8,
glucose 10, and HEPES 20 (pH 7.2 with NaOH). Stock solutions of thapsigargin (Tg) were
prepared in DMSO at a concentration of 1 mM.
3.3.7. Membrane Proteins Biotinylation
The isolation of membrane proteins in U266 cells was done using the Pierce™ Cell Surface
Biotinylation and Isolation Kit (Thermo Fisher, A44390). In brief, 1x106 cells/ml were treated
with MTI-101 (20 µM) for 10 minutes in Live Cell Imaging Solution followed by resuspension in
the Biotin containing solution. Cells were then lysed with the kit’s lysis buffer. A BCA assay was
done to ensure equal loading of protein (1mg) to the NeutrAvidin Agarose beads. The elute from
the beads and control whole cell lysates we subjected to Western blot analysis.
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3.3.8. Co-immunoprecipitation
Co-immunoprecipitation protocol was adapted from Hofmann et al [33]. Briefly, 10x106 cells were
treated with 20 µM of MTI-101 for 10 minutes in Live Cell Imaging Solution (Molecular Probes
by Life Technologies), centrifuged at 4 ºC and lysed with 1% Triton X-100 (Thermo Scientific;
85111) in PBS, with protease and phosphatase inhibitors cocktail (Millipore Sigma). BCA assay
was used to quantify protein concentration. 1 mg of protein for each treatment and control groups
were incubated with the primary antibody (TRPC1; Santa Cruz Biotechnology, and host species
IgG) overnight rotating in 4ºC. Later, protein A/G plus agarose (Santa Cruz Biotechnology; sc2003) was added to the sample and allowed to incubate rotating in 4 ºC for one hour. Samples
were washed 3x in lysis buffer and samples were subjected to Western blot analysis.
3.3.9. TRPC1 Cleavage Analysis
U266, MM.1s, or HS-5 cells were seeded at a density of 7x105 cell/ml in 10 ml Live Cell Imaging
solution at 37 ºC in 5% tissue culture incubator. 15 µM MTI-101, 2 µM thapsigargin, and 80 µM
calpeptin were used to treat appropriate samples and cells were collected at 5, 30, 60, and 90
minutes post treatment. Following drug treatment cells were lysed using 1X RIPA buffer (Thermo
Fisher) with protease and phosphatase inhibitors cocktail (Protease Inhibitor Cocktail Set III,
Millipore Sigma; 539135, and Phosphatase Inhibitor Cocktail Set II, Millipore Sigma; 524625) for
30 minutes on ice. Lysates were spun down and supernatant was taken off, the pellet was then
resuspended in 1X RIPA buffer plus 2% SDS and lysed for 30 minutes on ice. Pellets was then
sonicated using a probe homogenizer. Protein concentration from both compartments were
measured using Pierce BCA Protein analysis kit, and 30 µg were analyzed using Western blot.
Cleavage of TRPC1 using recombinant calpain-1 was adopted from Kaczmarek et al. In short,
U266 and HS-5 cells were collected at 7x105 cells/ml, resuspended and sonicated in Live Cell
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Imaging Solution (Molecular Probes; Life Technologies). Lysates were incubated in the presence
of 2.5 mM CaCl2, 50 ug/ml recombinant calpain-1 (LSBio) and in the presence or absence of 80
µM calpeptin. Extracts were incubated at room temperature for 1 hour to allow for enzymatic
cleavage. After the incubation, cell lysates were subjected to Western blot analysis for the
detection of full length and cleaved TRPC1.
3.3.10. Survival Analysis with Multiple Myeloma Patients
Overall survival analysis was done using expression data (in transcripts per million) and overall
survival records (in days) from newly diagnosed MM patients enrolled in the CoMMpass trial
(release IA14), downloaded from the Multiple Myeloma Research Foundation researcher gateway
(https://research.themmrf.org/). Additional overall survival analysis was conducted using
microarray expression data and overall survival records (in days) for patients with relapsed
myeloma obtained the APEX/SUMMIT trail (GEO accession #: GSE9782) [34]. The survival
curves were generated with the survival R package, and P value was calculated by log-rank test.
3.3.11. Statistical Analysis
Cell death percentage is reported as a representative of experiment performed in quadruplicate,
one-way ANOVA was used to determine significance (p<0.05), and Tukey's multiple comparisons
test was used to determine significance between groups. Ca2+ and Na+ influx measurements were
done by measuring the fluorescence intensity of 50 cells and subtracting the baseline fluorescence
intensity. We reported the mean of 50 cells with error bars representing the standard error of the
mean (SEM), and a single cell that fell in the median. Response magnitudes were quantified by
measuring the Maximum Peak and integrating the area under the curve (Peak AUC), respectively,
for the first 30 minutes. Peak AUC was measured using GraphPad Prism (GraphPad Prism,
RRID:SCR_002798) by following the trapezoid rule using the equation ΔX*([(Y1+Y2)/2]75

Baseline] to calculate the area. Significance was determined by one-way ANOVA (p<0.05), and
Tukey’s multiple comparisons test was used to determine in-between groups significance. All
experiments were done three independent times, and shown is a representative experiment. mRNA
expression analysis was done by Quantitative real-time PCR 3 independent times from 3 different
days in triplicates. We reported the mean of the three experiments by calculating delta CT (Cycle
Threshold) and subtracting the CT of the mRNA of interest from GAPDH. For siRNA knockdown
experiments, we reported the fold change in expression by measuring the ratio of siRNA of interest
to the siControl. We reported the mean of three independent experiments as well.
3.4 Results
3.4.1. MTI-101 Induces Sustained Ca2+ Flux Leading to Cell Death
We previously reported MTI-101 induced cell death in U266 and H929 MM cells through
increased calcium flux leading to necrotic cell death [32]. To determine the involvement of SOCE
pathway in MTI-101 induced cell death, we treated MM cells U266, MM.1s and the fibroblast
stroma cell line HS-5 with MTI-101 and thapsigargin, and measured Ca2+ influx and cell death.
MTI-101 treatment induced a delayed, and irreversible Ca2+ influx with peak accumulation
occurring between 10 and 30 minutes. Thapsigargin induced a rapid, and robust Ca2+ influx in both
U266 (Fig. 1 A, C, G, H, and M) and MM.1s cell lines (Fig. 1 B, D, I, and J) that peaked within
the first five minutes of application. In the presented data in Fig. 1 C and D, we selected a cell
representing the median Ca2+ peak of the 50 analyzed cells. Because time to peak varies in-between
cells, this reshapes the curves when averaging the population (Fig. 1 A and B). MTI-101-induced
cell death closely paralleled the time corresponding to the peak Ca2+ level (Fig. 1 E and F). HS-5
cells were treated with the same dose of MTI-101 (20 µM) and thapsigargin (1 µM) for the same
treatment period (Supplementary Fig. S1 A-C). Interestingly, MTI-101 did not induce Ca2+ influx
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in HS-5 cells throughout the treatment period, while thapsigargin induced a rapid and robust Ca2+
influx, similar to MM cell lines. The lack of induction of Ca2+ influx correlated with the finding
that MTI-101 did not induce cell death in HS-5 cells (Supplementary Fig. 1 D). Collectively, these
data suggest that MTI-101 induced cell death in MM cells is correlated with a sustained, delayed,
and irreversible Ca2+ influx, unlike thapsigargin which induces a rapid and reversible Ca2+ influx,
that is not sufficient to induce immediate cell death.
3.4.2. Extracellular Na+/ K+/ Ca2+ contribution to MTI-101 activity
We next sought to determine the role of specific ions in mediating MTI-101-induced Ca2+
cytotoxicity. The Orai1 channel demonstrates high specificity for Ca2+ [35,36], whereas TRPC
channel complexes are less specific for Ca2+ and additionally permeate both Na+ and K+ as well
[21]. To learn more about the role of Na+ in MTI-101-mediated cytotoxicity, we first asked the
question whether MTI-101 treatment induced Na+ influx. We addressed this question using the
Na+ sensitive fluorescent dye ION NaTRIUM Green-2 AM, to measure the level of Na+ influx
following MTI-101 treatment in both Na+-Ringer and NMDG-Ringer solutions (devoid of Na+ but
contains the non-permeable monovalent cation N-methyl-d-glucamine or NMDG). MTI-101
treatment induced a peak in Na+ accumulation within ten minutes, similar to the pattern of MTI101-induced Ca2+ entry. The Na+-sensitive fluorescence signal was significantly diminished but
not completely abolished in cells bathed in Na+-free NMDG solution, suggesting a low degree of
background fluorescence (Fig. 2 A). As shown in Fig. 2 B, replacing Na+ with NMDG was not
sufficient to attenuate MTI-101-induced cell death. MTI-101 did however, increase U266 cell
permeability to Na+. Together, these data indicate that MTI-101 treatment induced activation of a
Na+-permeable cationic channel, even though sodium influx per se does not play an apparent role
in MTI-101-induced cell death.
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To address the role of Ca2+ entry in MTI-101 induced cytotoxicity, we reduced extracellular CaCl2
from 2.5 mM to 5 µM CaCl2 and measured MTI-101 mediated Ca2+ accumulation and cell death.
Decreasing external Ca2+ significantly reduced MTI-101 mediated Ca2+ influx (Fig. 2 C).
Furthermore, decreasing extracellular Ca2+ significantly attenuated MTI-101 induced cell death by
34% in U266 cells (Fig. 2 D). Unlike Na+, extracellular Ca2+ contributes to MTI-101 mediated cell
death.
Calcium signaling in immune cells is modulated by K+ conductance that regulate the driving force
for Ca2+ entry [37,38]. Plasma membrane potential is largely set by the K+ equilibrium across the
membrane, and this in turn establishes the inward driving force for Ca2+. We sought to determine
whether lowering the driving force for Ca2+ entry by depolarizing cells would modulate the
potency of MTI-101. STIM1/Orai1 are continuously active in patch clamp experiments following
store depletion by IP3 or ionomycin [15]. Further, when extracellular Ca2+ is depleted, and intact
cells are treated with thapsigargin or cyclopiazonic acid, a large Ca2+ influx occurs when Ca2+ is
re-added to the extracellular solution. This Ca2+ influx is attributed to the SOCE pathway and Ca2+
entry is driven by the negative membrane potential. However, in Jurkat T cells, when extracellular
K+ levels are increased to 140 mM, the membrane potential collapses to 0 mV and Ca2+ entry is
diminished due to the reduction in driving force. To test the effect of high extracellular K+
concentration on MTI-101-induced Ca2+ entry, we compared MTI-101-mediated Ca2+ entry among
cells bathed in either physiological saline solution (3 mM KCl) or high K+ (50 mM KCl) saline
solution. Elevated external K+ reduced Ca2+ accumulation by 55.6% (Fig. 2 E). Furthermore, high
extracellular K+ concentration completely abolished MTI-101-induced cell death (Fig. 2 F).
Moreover, we measured the membrane potential for the respective treatment groups in Fig. 2 G
using the membrane-potential sensitive dye DIBAC4(3) in U266 cells (Fig. 2 G). As expected, 50
mM KCl PSS resulted in membrane depolarization. MTI-101 treatment also increased dye
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fluorescence indicative of strong depolarization, likely caused by membrane depolarization due to
Na+ influx through non-selective cation channels. Combining high K+ depolarization with MTI101 failed to further depolarize the membrane potential of cells already depolarized by 50 mM
KCl. Collectively, these data indicate that Ca2+ influx is the predominant driver for MTI-101mediated cell death, and reducing Ca2+ influx either by reducing extracellular Ca2+, or reducing
the driving force for Ca2+ diminishes MTI-101-mediated cell death.
3.4.3. Pharmacological inhibition of TRPC channels block MTI-101 induced Ca2+/Na+
influx and cell death in MM cell lines and inhibition of CRAC channels inhibits MTI-101
induced Ca2+ influx and cell death
Even though Na+ influx was not responsible for cell death, experimental data indicated that MTI101 treatment resulted in influx of both Na+ and Ca2+, prompting us to determine the role of TRPC
channels in mediating the influx of these ions. We initially sought to use pharmacological tools to
delineate the role of TRPC channels in mediating MTI-101 induced cell death. SKF96365 is a
somewhat non-specific inhibitor of receptor-mediated Ca2+ entry pathways (RMCE) and SOCE
[39,40]. We pre-treated U266 cells with SKF96365 (25 µM) for 1 hour and measured Ca2+ influx
in the presence of MTI-101 and Tg, respectively (Fig. 3 A and B). Cells pre-treated with SKF96365
showed a significant reduction in Ca2+ entry when stimulated with either MTI-101 (Fig. 3 A) or
Tg (Fig. 3 B). SKF96365 reduced peak Ca2+ accumulation evoked by MTI-101 by 80%, and
decreased the peak Tg-induced Ca2+ response by 51% (Fig. 3 C). Because SFK96365 treatment
blocked the Tg-induced Ca2+ response these data suggest that SKF9635 likely also blocks CRAC
channels and therefore precludes a clear discrimination between CRAC and TRPC-mediated Ca2+
influx in MM cells.
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To further test the idea that the MTI-101-mediated ion influx might be carried at least in part by
TRPC channels that can conduct both Na+ and Ca2+, we asked whether SKF96365 could inhibit
MTI-101- mediated Na+ influx. SKF96365-pretreatment significantly reduced Na+ accumulation
in U266 cells by 29% measured by average maximum Na+ peak of 50 cells (Fig. 3 D) and decreased
MTI-101-induced cell death in both U266 and MM.1 cells by 58% and 38%, respectively (Fig. 3
E and F). These data suggest that MTI-101 activates a non-specific cation channel that contributes
to MM cell death and can be modulated by pre-treatment with SKF96365.To address the role of
CRAC channels on MTI-101-induced cell death and Ca2+ influx, we pre-treated U266 cells with
CRAC specific inhibitor GSK7975A (Fig. 3 G). GSK7975A (10 µM) attenuated MTI-101-induced
cell death by 32%. GSK7975A attenuated thapsigargin-induced Ca2+ influx, indicating the
specificity of the drug towards CRAC activity, and significantly reduced MTI-101 induced Ca2+
influx (Fig. 3 H). , Taken together, the CRAC channels inhibitor GSK7975A attenuates MTI-101
induced Ca2+ influx and cell death.
3.4.4. TRPC4/5 channel contributes to MTI-101 induced Ca2+/Na+ influx and cell death
We previously created a MM cell line resistant to HYD-1 (linear MTI-101) H929-60, and reported
a down regulation of multiple genes contributing to Ca2+ entry pathways including TRPC1,
ATP2A3, PLC-β, ITPR3 and TRPM7 [32]. Further, we reduced the expression of TRPC1 via
shRNA and noted a reduction in MTI-101 induced cell death. Moreover, the broad-spectrum IP3
and TRPC channel inhibitor 2-APB significantly inhibited MTI-101 induced cell death in relapsed
MM patients’ specimens, U266 and H929 cell lines [32]. The TRPC family is comprised of seven
members, and functional TRPC1-containing channels are formed by heterodimeric and
heterotetrameric arrangements of subunits (e.g. TRPC1/4, TRPC1/5, TRPC1/4/5) [22,24,41]. To
learn more about the possible components of TRPC channels expressed in MM cells, we measured
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the expression levels of TRPC1, TRPC4 and TRPC5 in MM cell lines by quantitative real-time
PCR in U266 and MM.1s cell lines. Interestingly, TRPC1 and TRPC5 were both abundantly
expressed in U266, MM.1s and HS-5 while TRPC4 was only expressed in U266 and HS-5 (Fig. 4
A). To determine the role of TRPC4 in MTI-101 induced cell death, we pretreated U266 and
MM.1s cells with ML204 (20 µM), a selective inhibitor of TRPC4 and TRPC5 channels, with no
reported selectivity towards other TRP family members [42]. Pre-treated U266 cells showed a 49%
significant attenuation to MTI-101-induced cell death, with only 22% attenuation in MM.1s cells
(Fig. 4 B and C). These data suggest that pharmacological inhibition of TRPC4 and TRPC5
moderately reduced MTI-101 cytotoxicity. The efficacy of ML204 may have been confounded by
the heterogeneity of TRPC channel complexes.
To further address the role of TRPC4, small interfering-RNA (siRNA) was used to reduce the
expression of TRPC4 (Fig. 4 D). Reducing the expression of TRPC4 significantly inhibited MTI101 induced cell death by 50%, supporting the role of TRPC4 in MTI-101-mediated cell death
(Fig. 4 E). Interestingly, Ca2+ influx was significantly reduced by 57% in MTI-101 treated TRPC4
knockdown cells, but was not attenuated in the Tg-treated cells (Fig. 4 F), indicating that both
SOCE and RMCE pathways may contribute to Ca2+ influx independently.
To test whether TRPC5 expression is a determinant in MTI-101 induced Ca2+ influx and cell death,
we used siRNA to knockdown TRPC5 expression in U266 and MM.1s cell lines (Fig. 5 A).
Reducing TRPC5 expression attenuated MTI-101 induced cell death by 60% and 36% in U266
and MM.1s respectively (Fig. 5 B and C). Furthermore, cells with reduced expression of TRPC5
showed a significant reduction in MTI-101 induced Ca2+ influx by 37% and 33% in both cell lines,
respectively, similar to what was observed by reducing TRPC4 expression (Fig. 5 D and E).
Finally, TRPC5 knockdown had no discernable effect on peak Tg-induced Ca2+ influx levels (Fig.
5 D and E). Taken together, these data indicate that TRPC4 and TRPC5 significantly contribute to
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the MTI-101 induced Ca2+ influx and cell death, and delineates a role of TRPC channels in MTI101-mediated Ca2+ influx in parallel to the canonical SOCE pathway.
3.4.5. MTI-101 activity is dependent on STIM1/TRPC1 trafficking and heteromeric
assembly in the plasma membrane
TRPC1 appears to contribute to the sustained Ca2+ influx following MTI-101-induced signaling in
parallel with the canonical SOCE pathway, as has been previously reported [43]. To determine
whether STIM1 was necessary for MTI-101-mediated Ca2+ entry, we examined the effect of
knocking down STIM1 expression by siRNA on Ca2+ signaling (Fig. 6 A and B). Reducing STIM1
expression decreased the Tg-evoked rise in store operated Ca2+ entry by 40%, and reduced MTI101-mediated Ca2+ entry by 64%. ISOC currents mediated by STIM1/TRPC1 complex occurs
following the trafficking of TRPC1 to the plasma membrane following the initial activation of
STIM1/Orai1 [44]. To confirm that MTI-101 induces trafficking of TRPC1 to the plasma
membrane, we treated U266 and MM.1s cells with MTI-101 (20 µM and 25 µM, respectively) for
10 minutes followed by a membrane biotinylation of surface proteins (Fig. 6 C and D). Cells
treated with MTI-101 showed an increased level of TRPC1 in comparison to control. We utilized
p27 as a cytoplasmic/nuclear control of protein to ensure increased levels of TRPC1 were not due
to MTI-101 induced increases of the permeability of the chemical probe and increases of the
detection of cytoplasmic protein. To confirm that TRPC1 trafficking is facilitated by binding to
STIM1, we demonstrate the binding of TRPC1 to STIM1 at the 10 minutes time points in U266
and MM1.s cells in Fig. 6 E and F. These findings support the hypothesis that MTI-101 activity is
dependent on STIM1 expression, TRPC1 trafficking and incorporation into the plasma membrane
and a STIM1/TRPC1 complex formation.
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3.4.6. MTI-101 induces TRPC1 Truncation by Calpain Activation
Kaczmarek and colleagues reported that the Ca2+ activated proteases calpain I/II cleaves and
further activate TRPC5 in neuronal cells in the presence of semaphorin 3A [45]. Further, they
reported that the calpain inhibitor calpeptin blocks the cleavage and attenuates downstream Ca2+
currents. In addition, the Ca2+ influx through TRPC1 activity is reported to activate calpains [46].
The additional impact provided by MTI-101 activity is the absence of a turn off switch to the Ca2+
currents, resulting in sustained Ca2+ entry and leading to cell death. To determine the potential role
of calpain I/II in MTI-101 effects, we treated cells with MTI-101 (15 µM) and Tg (1 µM) and
analyzed the RIPA insoluble cellular compartment via Western blot analysis (Fig. 7 A).
Interestingly, we noticed a cleaved TRPC1 fraction at 60 kD molecular weight only with MTI-101
treatment. Further, we noticed decreased levels of TRPC1 cleaved fractions when we pre-treated
cells with calpeptin (80 µM) in U266 and MM.1s cells (Fig. 7 B and C, and Supplementary Fig.
S2 A and B). Moreover, calpeptin pre-treatment significantly reduced Ca2+ influx and MTI-101induced cell death (Fig. 7 D and E). To assess whether TRPC1 cleavage is calpain I - dependent,
we treated sonicated U266 and HS-5 stroma lysates with recombinant calpain I (Fig. 7 F, and
Supplementary Fig. 2 C). Recombinant calpain I cleaved TRPC1 at approximately the same
molecular weight as the downstream effect of MTI-101 treatment. Furthermore, pre-treatment with
the calpain inhibitor calpeptin blocked the cleavage of TRPC1 (Supplementary Fig. 2 D). We
found that TRPC1 in HS-5 stroma cells are prone to cleavage by active calpain I, while MTI-101
did not show any associated TRPC1 cleaved fraction (Supplementary Fig. S2 E). Previously we
reported that decreasing TRPC1 protected from MTI-101 induced cell death[32]. To test the effect
of TRPC1 on MTI-101-induced Ca2+ influx, we used siRNA to knockdown TRPC1 expression in
U266 and MM.1s cell lines (Fig 7. F and Supplementary Fig. S2 F).Reducing TRPC1 expression
attenuated MTI-101 induced cell death by 48% and 20% in U266 and MM.1s respectively,
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furthermore, calpain pre-treatment in cells with reduced TRPC1 expression attenuated MTI-101
effect by 72% and 76% in both cell line respectively (Fig. 7 G and Supplementary Fig. S2 G).
Reducing TRPC1 showed a significant reduction in MTI-101 induced Ca2+ influx in both cell lines,
and calpain pre-treatment contributed to increased reduction in Ca2+ levels (Fig. 7 H and
Supplementary Fig. S2 H). In aggregate, these data suggest that calpain I activation following
MTI-101 treatment contributes to the sustained Ca2+ influx, and potentially is a feed forward loop
for activation of TRPC containing channels following treatment with MTI-101 in MM cells.
3.4.7. Members of the SOCE pathway correlates with poor patient outcomes
Aside from the SOCE role in replenishing ER/SR Ca2+ stores, the extracellular Ca2+ influx through
TRPC regulates multiple Ca2+-dependent gene expressions patterns (ex. NFAT pathway) [47].
Increased TRPC1 expression has been reported to contribute to pancreatic cancer cell motility,
breast cancer, non-small cell lung cancer, colon cancer, and glioblastoma multiforme proliferation
and migration [48-52]. Further, we previously discussed the role of Ca2+ homeostasis in cancer
progression. Interestingly, this class of compounds is more active in CD138 cells isolated from
MM patients that have relapsed compared to newly diagnosed patients [30,32]. These data suggest
that determinants of MTI-101 sensitivity including the SOCE pathway maybe upregulated in
aggressive MM disease. Thus, we sought to determine whether expression of the components of
the SOCE pathway correlate with aggressive disease. To address this question, we used two
publically available gene expression datasets with paired patient survival data. The COMPASS
data set is multi-site trial initiated by MMRF [53]. Expression profiling was based on newly
diagnosed specimens using RNA-SEQ as the platform (Fig. 8 A). The APEX/SUMMIT data was
a multi-site international trial for patients enrolled in Phase II and Phase III clinical trials of
Bortezomib [34].Thus these patients were relapsing on current therapy prior to proteasome related
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regimens. The expression profiling platform was GeneArray 3000 Affymetrix for this study. As
shown in Fig. 8 A and B, multiple components of the SOCE pathway were poor or unfavorable
prognostic markers in both studies. Interestingly, TRPC components were not as strong predictors
compared to STIM1. However, these data do not rule out that a readout of activity such as plasma
membrane localization of TRPC1 may be required for prediction of disease outcome. Future
studies will address the role of membrane localized TRPC1 as a prognostic indicator for MM
progression. In Fig. 8 C we show a working model for the mechanism of action of MTI-101 based
on the current data presented in this manuscript and previously reported data [30-32].
3.5 Discussion and Conclusions
Ca2+ entry through SOCE regulates multiple genetic pathways, where Ca2+ signals through CRAC
currents activate the NFAT and NFkB pathways; Ca2+ currents through TRPC1 and the ISOC
complex predominantly activate the NFkB pathway [47,54,55]. Although TRPC1 expression
contributes to various tumor outcomes, its over expression is predominantly and most consistently
correlated with poor cancer outcomes in lung, pancreatic, breast, glioblastoma multiforme, and
colon cancers [24,48-52]. In this study we show that RNA expression of components of the SOCE
pathway correlates with poor survival in newly diagnosed MM patients when examining the
expression levels in 1150 patients using the CoMMpass dataset and 669 relapsed patients in the
APEX/SUMMIT trial. Based on these data it is intriguing to speculate that increased capacity to
respond to the RMCE/SOCE pathway is required for aggressive disease and potentially contributes
to the emergence of drug refractory disease. Interestingly, at the RNA level STIM1/ORAI was a
stronger prognostic indicator compared to components of TRPC. However, considering our data
indicating that TRPC1 needs to be trafficked to the cell membrane, it is feasible that protein
localization rather than absolute expression levels might be a determinant of aggressive disease.
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This signature may lead to strategies to pharmacologically block this pathway or conversely,
represents an Achilles heel of aggressive disease having increased susceptibility to cell death via
Ca2+ overload. With that in mind, targeting Ca2+ homeostasis, and more specifically the SOCE
pathway presents a novel pathway for the treatment of MM.
Our findings indicate that the MTI-101 mechanism of action is different from the standard blocker
of the SERCA pump thapsigargin. While thapsigargin inhibits SERCA function causing rapid
depletion of the ER Ca2+ stores, MTI-101 treatment induces a more delayed and sustained Ca2+
entry. This difference could be attributed to the ICRAC currents through STIM1 coupling with Orai1
activity, while MTI-101 is mostly dependents on ISOC currents through STIM1/TRPC1/4/5
activity, but not completely independent of STIM1/Orai1 activity. Baudel and colleagues
previously reviewed the role of SOCE in vascular smooth muscles (VSMCs) contractility, where
cells isolated from mice with Orai1-/- were capable of activating the SOCE pathway via STIM1
and TRPC1 only [56,57]. Furthermore, Romani et al reported that in arterial myocytes Orai1
expression levels were inherently low in the contractile phenotype, yet maintained SOCE activity,
while the proliferative phenotype showed increased expression of Orai1, STIM1, and TRPC1 [58].
In contrast, it has been reported that in salivary glands, ISOC currents mediated through STIM1 and,
TRPC1 interaction is dependent on prior activation of STIM1/Orai1, and the knockdown of Orai1
abolishes TRPC1 activation [59].
Owing to this diversity in TRPC1 mode of activation, it is conceivable that MTI-101 activity could
be dependent on coupling STIM1 and TRPCs in MM cells. Consistent with this notion, we
observed that MTI-101-induced cell death is partially dependent on the expression of TRPC1/4/5,
suggesting that they participate in the complex formation with STIM1. We further report that in
an inactive state, and in absence of MTI-101, we failed to detect TRPC1 at the plasma membrane,
and the activation of the SOCE pathway by MTI-101 allowed TRPC1 trafficking and insertion
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into the plasma membrane. TRPC1 recycling to and from the plasma membrane following SOCE
activation has been reported previously by De Souza and colleagues [60]. They reported that the
TRPC1 fast recycling is dependent on trafficking to the plasma membrane by Rab4 and the
internalization into Rab5-containing endosomes is an ARF6-dependent pathway. Future studies
will determine the mechanism underpinning MTI-101-induced trafficking of TRPC1 to the plasma
membrane. We propose that MTI-101 is a unique tool for delineation of TRPC1 membrane
trafficking.
The Ca2+-activated protease calpain 1 is associated with poor survival in MM patients in the
COMPASS dataset. Kaczmarek et al reported that the pharmacological inhibition of calpain I/II
inhibited TRPC5 [45]; further, Verheijden and colleagues reported that TRPC6 contributes to
calpain I activation, and pharmacologically inhibiting calpain I or genetically knocking it down
abrogated TRPC6 effects on podocyte injury in the kidneys [61]. Other reports indicated that Ca2+
entry through active TRPC1 activates calpain I in neurons and regulates axon outgrowth [46]. Our
findings indicated that MTI-101 treatment induces cleavage of TRPC1 and that TRPC1 is a
substrate for recombinant calpain I. In addition, pharmacological inhibition of calpains blocked
MTI-101-induced calcium influx and cell death. Based on these data it is attractive to reason that
the calpain-dependent feed-forward loop is due to cleavage of TRPC1 either via induction of a
higher conductance or open probability of the channel. Further studies are required to determine
the functional consequence of TRPC1 cleavage on MTI-101-induced calcium and sodium entry.
Cleavage of TRPC1 was targeted in cells sensitive to MTI-101, while cleavage was not observed
in the stroma cell line HS-5. However, Ca2+-activated recombinant calpain I was able to cleave
TRPC1 from HS-5 derived lysates. These finding correlate with failure of MTI-101 to evoke a
calcium response in HS-5 stroma cells. Again, more studies are required to fully understand the
mechanism underpinning the MTI-101-induced trafficking of TRPC1 to the plasma membrane,
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and its continuous activation leading to the sustained Ca2+ influx and cell death. In summary, MTI101 is a novel drug that leverages one of the cancer cells’ main survival machinery, the augmented
Ca2+ circuitry. Future studies will define the dependency of TRPC1 for survival in the bonemarrow microenvironment and whether this signaling pathway is required for growth, cell
adhesion-mediated drug resistance (CAM-DR) or soluble mediate drug resistance (SM-DR). Our
data support a unique mechanism of Ca2+-induced necrotic cell death, and the targeting of storeoperated Ca2+ entry pathways for the treatment of multiple myeloma.
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure
S1: Stroma cells are not sensitive to MTI-101-induced Ca2+ flux and cell death, Figure S2: MTI101 induces TRPC1 Truncation by Calpain Activation
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3.7 Figure Legends
Figure 1: MTI-101 treatment Induces Sustained Ca2+ Flux and cell death in two independent
MM cell lines: A and B) The effect of MTI-101 was compared to thapsigargin (Tg) by measuring
Ca2+ influx using Fluo-4-AM fluorescence intensity in U266 (A) and MM.1s (B) cell lines. The
line graph shows the mean and standard error of the mean (SEM) of 50 cells fluorescence after
subtracting the baseline over one hour. Cells were treated with MTI-101 (20 µM for U266, and 30
µM for MM.1s), Tg (1 µM), and vehicle control and imaged every 30 seconds. Shown is a
representative experiment (n=50 individual cells). C and D) Shown is a single cell tracing for Ca2+
influx following treatment from figures A and B. The individual cells were chosen based on the
median peak for Ca2+ influx for the re-spective treatment group. E and F) Overlay of Fluo-4-AM
and DAPI fluorescence in a single cell following MTI-101 treatment over one hour. G and H)
Mean maximum peak of Ca2+ influx in 50 cells in U266 and MM.1s cell lines. I and J) The total
levels of Ca2+ influx mediated by MTI-101, Tg, and vehicle control was measured by calculating
the peak area under the curve (Peak AUC) of the 50 cells. K and L) The effect of MTI-101 (20
µM) and Tg (1 µM) on cell death was measured in U266 and MM.1s cell lines by imaging the
respective treatment group every 5 minutes for one hour. Cell death was determined by a threshold
of DAPI fluorescence indicative of a dead cell. M) Fluo-4-AM and DAPI pre-loaded U266 cells
were used as indicators for Ca2+ uptake and cell death, respectively. Cells were imaged every 30
seconds at 10X using the BIOTEK Cytation 5 imager. All experiments were repeated three
independent times, and shown is a repre-sentative experiment. Error bars represent SEM (p<0.05
One-way ANOVA, inter-group comparison was done by Tukey's multiple comparisons test).
Figure 2: Extracellular Na+/ Ca2+ / K+ contribution to MTI-101 activity: A) Shown is a single
cell tracing for Na+ influx following treatment with MTI-101 (20 µM) in U266 cells . Na+ influx
98

was measured using the Na+ indicator ION NaTRIUM Green-2 AM, and was imaged every 30
seconds. The individual cells were chosen based on the median peak for Na+ influx for the
respective treatment group. Mean maximum peak of Na+ influx in 50 cells in U266. B) The effect
of MTI-101 (20 µM) on U266 cell death was measured by imaging the respective treatment groups
in NaCl-ringer or NMDG-ringer solutions every five minutes for one hour. C and E) Single cell
tracing Ca2+ levels for U266 cells in 5 µM CaCl2, 50 mM KCl and physiological saline solutions
with MTI-101 (20 µM). Cells were imaged every 30 second. Mean maximum peak of Ca2+
fluorescence in 50 cells. D and F) The effect of MTI-101 (20 µM) on U266 cell death in 5 µM
CaCl2, 50 mM KCl and physiological saline solutions. Cells were imaged every five minutes. G)
Fluorescence of DIBAC4(3) pre-loaded U266 cells treated with MTI-101 (20 µM) in either 50 mM
KCl, or physiological saline solutions (3 mM KCl). Presented fluorescence data were measured
by subtracting the mean control fluorescence of cells in 3 mM KCL PSS buffer from all other
treatment groups. Cells were imaged every 30 seconds for 1 hour. Error bars represent SEM
(p<0.05 One-way ANOVA, inter-group comparison was done by Tukey's multiple comparisons
test). All experiments were repeated three independent times, and shown is a representative
experiment.
Figure 3: Pharmacological inhibition TRPC channels blocks MTI-101 induced Ca2+/Na+
influx and cell death in MM cell lines and inhibition of CRAC channels inhibits MTI-101
induced Ca2+ influx and cell death: A and B) The effect of blocking non-specific cation channels
was tested using the inhibitor SKF96365 (25 µM) in combination with MTI-101 (20 µM) and Tg
(1 µM) on U266 cell line. Ca2+ influx fluorescence signal was measured every 30 seconds in a
single cell. The individual cells were chosen based on the median peak for Ca2+ influx for the
respective treatment group. C) Mean maximum peak of Ca2+ influx in 50 cells in U266 cell line.
D) Single cell tracing of Na+ influx in cells pre-treated with SKF96365 (25 µM) followed by MTI99

101 (20 µM) treatment. Cells were imaged every 30 seconds. The individual cells were chosen
based on the median peak for Na+ influx for the respective treatment group. E and F) The effect
of SKF96365 (25 µM) and MTI-101 (20 µM) on cell death was measured in U266 and MM.1s
cell lines. Cell death was measured every five minutes. G) The effect of blocking CRAC channels
was determined using the inhibitor GSK7975A (10 µM) in combination with MTI-101 (20 µM)
on U266 cell death. Cell death was measured every five minutes. H) Single cell tracing Ca2+ levels
for GSK7975A (10 µM) pre-treated U266 cells followed by MTI-101 (20 µM) or Tg (1 µM). Cells
were imaged every 30 second. Mean maximum peak of Ca2+ fluorescence in 50 cells. Error bars
represent SEM (p<0.05 One-way ANOVA, inter-group comparison was done by Tukey's multiple
comparisons test).
Figure 4: TRPC4 channel contributes to MTI-101 induced Ca2+/Na+ influx and cell death:
A) TRPC1, TRPC4, and TRPC5 mRNA relative expression levels in U266, MM.1s, and HS-5 cell
lines. Abundance of expression is shown for the respective mRNA compared to GAPDH in each
cell line. Experiments were done in triplicates three independent times. Shown is the mean of the
three experiments. B and C) The effect of ML204 (20 μM) pre-treatment on U266 and MM.1s
cell death with MTI-101 (20 μM and 30 μM respectively). Error bars represent SEM, experiments
were done three independent times, shown is a representative single experiment (p<0.05 One-way
ANOVA). D) TRPC4 mRNA fold change expression in U266 with siTRPC4 relative to U266 with
siControl is shown. SEM of three independent experiments is shown (p<0.05 student t-Test). E)
Effect of knocking down TRPC4 in U266 cell death by MTI-101 (20 μM). Experiments were done
three independent times, and shown is a single representative experiment (p<0.05 One-way
ANOVA). F) Single-cell tracing for Ca2+ influx in Fluo-4-AM preloaded U266 cells with siTRPC4
and siControl. Cells were treated with MTI-101 (20 μM) and Tg (1 μM). Cells were imaged every
30 seconds for one hour.
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Figure 5: TRPC5 channel contributes to MTI-101 induced Ca2+/Na+ influx and cell death:
A) TRPC5 mRNA fold change expression in U266 and MM.1s with siTRPC5 relative to siControl
cell lines. SEM of three independent experiments is shown (p<0.05 student t-Test). B and C)
Effect of knocking down TRPC5 in U266 and MM.1s on cell death mediated by MTI-101 (20 µM
and 30 µM respectively). Experiments were done three independent times, and shown is a single
representative experiment (p<0.05 One-way ANOVA). D and E) Single cell tracing for Ca2+
influx in Fluo-4-AM loaded U266 and MM1.s cells with siTRPC5 and siControl. Cells were
treated with MTI-101 (20 μM) and Tg (1 μM). Cells imaged every 30 seconds for one hour. Mean
maximum peak of Ca2+ influx in 50 cells in U266 and MM.1s cell lines. Error bars represent SEM
(p<0.05 One-way ANOVA, inter-group comparison was done by Tukey's multiple comparisons
test p<0.0001).

Figure 6: MTI-101 activity is dependent on STIM1/TRPC1 trafficking and heteromeric
formation in the plasma membrane: A and B) Ca2+ accumulation in populations of
approximately 60,000 U266 cells loaded with Fura-2AM with STIM1 siRNA or siControl. Cells
were treated with either MTI-101 (40 μM) or Tg (2 μM). Cells were imaged every 3 s for 30
minutes. Error bars show SEM. C and D) Detection of TRPC1 in the biotinylated membrane
proteins in U266 and MM.1s cell lines following treatment with MTI-101 (20 µM and 30 µM,
respectively) for 10 minutes. P27 used as cytoplasmic control and Integrin β1 is a plasma
membrane control. E and F) Co-localization detection of SOCE pathway proteins was done by
co-immunoprecipitation of STIM1 following MTI-101 treatment for 10 minutes in U266 and
MM.1s cells (20 µM and 25 µM, respectively). Experiments were done three independent times.
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Figure 7: MTI-101 induces TRPC1 Truncation by Calpain Activation: A) U266 cells treated
with MTI-101 (15 μM) and Tg (1 μM) for 5 and 30 minutes. TRPC1 cleaved fraction was detected
at ≈60 kDa only with MTI-101 treatment in RIPA insoluble cell fraction. B and C) U266 cells
pretreated with calpeptin (80µM) for one hour, followed by treatment with MTI-101 (15 µM) for
0, 5, 30, 60, 90 minutes. TRPC1 cleaved fractions was detected in the calpeptin-free group.
Quantification of the cleaved fraction TRPC1 normalized to β-actin. D) Single cell Ca2+ tracing
for Fluo-4-AM pre-loaded U266 cells pretreated with calpeptin (80 µM) for one hour. Cells were
imaged every 30 seconds for one hour. Mean maximum peak of Ca2+ influx in 50 cells in U266
cells. Error bars represent SEM (p<0.05 One-way ANOVA, inter-group comparison was done by
Tukey's multiple comparisons test p<0.05). E) The effect of calpeptin (80 µM) pretreatment on
MTI-101 induced cell death in U266 cells. Experiments were done in quadruplicates and repeated
three independent times. Error bars represent SEM (p<0.05 One-way ANOVA, inter-group
comparison was done by Tukey's multiple comparisons test p<0.05). F) CaCl2 activated calpain I
induced TRPC1 cleaved fraction at ≈60kDa in U266 cells. G) Western blot analysis for TRPC1
expression levels in U266 cells. H) Effect of knocking down TRPC1 in U266 cells on cell death
mediated by MTI-101 (20 µM) at 1 hour (p<0.05 One-way ANOVA). I) Single cell tracing for
Ca2+ influx in Fluo-4-AM loaded U266 with siTRPC1 and siControl. Cells were treated with MTI101 (20 μM) with or without one-hour pre-treatment with calpeptin (80 μM). Cells imaged every
30 seconds for one-hour. Mean maximum peak of Ca2+ influx in 50 cells in U266 cell line. Error
bars represent SEM (p<0.05 One-way ANOVA, inter-group comparison was done by Tukey's
multiple comparisons test p<0.0001).
Figure 8: Members of the SOCE pathway correlates with poor patient outcomes: A) Overall
survival analysis for selected components of the SOCE pathways for newly diagnosed MM
patients from the CoMMpass study. B) Overall survival analysis for selected components of the
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SOCE pathway for relapsed MM patients in the APEX/SUMMIT trail. p-value was determined by
log-rank test; (x) indicates expression data not available. Time is shown in days. C) A working
model for MTI-101 mechanism of action.
Supplementary Figures:
Figure S1: Stroma cells are not sensitive to MTI-101-induced Ca2+ flux and cell death: A and
B) The effect of MTI-101 was compared to thapsigargin (Tg) by measuring Ca2+ influx using Fluo4-AM fluorescence intensity in HS-5 cell line. The line graph shows a single cell tracing for Ca2+
influx following treatment with MTI-101 (20 µM) and Tg (1 µM). The individual cells were
chosen based on the median peak for Ca2+ influx for the respective treatment group. Cells were
imaged every 30 seconds. B) Mean maximum peak of Ca2+ influx in 50 cells in HS-5 cell line.
Error bars represent SEM (p<0.05 One-way ANOVA, inter-group comparison was done by
Tukey's multiple comparisons test p<0.05). C) The total levels of Ca2+ influx mediated by MTI101, Tg, and vehicle control was measured by calculating the peak area under the curve (Peak
AUC) of the 50 cells (p<0.05 One-way ANOVA, inter-group comparison was done by Tukey's
multiple comparisons test p<0.05). D) The effect of MTI-101 (20µM) and Tg (1µM) on cell death
was measured in HS-5 cells by imaging the respective treatment group every 5 minutes for one
hour. Cell death was determined by a threshold of DAPI fluorescence indicative of a dead cell.
Error bars represent SEM (p<0.05 one-way ANOVA).
Figure S2: MTI-101 induces TRPC1 Truncation by Calpain Activation: A and B) MM.1s
cells pretreated with calpeptin (80 µM) for one hour, followed by treatment with MTI-101 (25
µM) for 0, 5, 30 minutes. TRPC1 cleaved fractions was detected at ≈60 kDa in the calpeptin-free
group in the RIPA insoluble compartment. Quantification of the cleaved fraction TRPC1
normalized to β-actin. C) MTI-101 (15 µM) does not induce TRPC1 cleavage in HS-5 cells in
both RIPA Soluble and Insoluble compartments. D) CaCl2 activated calpain I induced TRPC1
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cleaved fraction at ≈60kDa in U266 cells following 1-hour incubation with the recombinant
protein. Pre-treating cells with calpeptin (80 µM) for 1 hour abrogated TRPC1 cleavage. E) CaCl2
activated calpain I induced TRPC1 cleaved fraction at ≈60kDa in HS-5 cells. Pre-treating cells
with calpeptin (80 µM) for 1 hour abrogated TRPC1 cleavage, while no cleavage was seen with
MTI-101 treatment. F) Western blot analysis for TRPC1 expression levels in MM.1s cells. G)
Effect of knocking down TRPC1 in MM.1s cells on cell death mediated by MTI-101 (30 µM) at
1 hour (p<0.05 One-way ANOVA). H) Single cell tracing for Ca2+ influx in Fluo-4-AM loaded
MM.1s with siTRPC1 and siControl. Cells were treated with MTI-101 (30 μM) with or without
one-hour pre-treatement with calpeptin (80 μM). Cells imaged every 30 seconds for one-hour.
Mean maximum peak of Ca2+ influx in 50 cells in MM.1s cell line. Error bars represent SEM
(p<0.05 One-way ANOVA, inter-group comparison was done by Tukey's multiple comparisons
test p<0.0001).
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Chapter 4 Conclusions and Future Directions
Multiple Myeloma advanced from untreatable to treatable malignancy yet is still incurable.
However, treatment options have been advancing over the decades. The first discovered treatment
was the autologous stem cell transplant (ACST) discovered in the 1980s’[1]. ACST was followed
by the discovery of novel agents including thalidomide and lenalidomide (IMID’s). Later,
treatment options further improved with the discovery of the proteasome inhibitors (PIs) lid by
bortezomib. More recently, elotuzumab and daratumumab categorized as monocolonal antibodies,
and Panobinostat the histone deacetylating agent has been approved by the US Food and Drug
Administration [2]. More recently, the FDA has approved idecabtagene vicleucel (Abecma) as
CAR-T therapy for multiple myeloma patients who failed or went through four different MM
treatments [3]. Moreover, The NCCN guidelines for the treatment of MM has treatment
recommendation for all stages of MM, including transplant and non-transplant patients. However,
With all these therapy, there is still an unmet need for a novel therapy targeting a novel pathway
for MM, especially with minimal residual disease outgrowth and contribution to drug resistance.
As we mentioned earlier the NFAT pathway contributes to proliferation, migration, and survival.
And to build on what Bucher and colleagues reported that NFAT activity is chronically elevated
in diffuse large B-cell lymphoma (DLCBCL), where the inhibition of calcineurin with cyclosporin
A or FK506 reduced cell death in DLCBCL, along with what was reported by Urso et al. where
NFAT3c is determinant of proliferation of and migration of glioblastoma cell lines [4,5] .It would
be intriguing to perform gene expression analysis on MM patients’ specimens to determine the
expression levels of genes regulated by the NFAT pathway, and to compare the levels in newly
diagnosed to relapsed specimens. Based on our data, MTI-101-induced cell death is greatly
dependent on the presence and activation of the SOCE pathway, as was previously reported that
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H929-60 MTI-101 resistant cell line showed downregulation of PLCβ, ITPR3, ATP2A3, TRPC1,
and TRPM7, all of which regulate the SOCE pathway. Furthermore, we reported that we are able
to attenuate MTI-101 induced Ca2+ influx and cell death using pharmacological inhibitors
targeting CRAC channels by GSK7975A, TRPC4 channel by ML204, and TRPC channels by
SKF96365. Establishing the link between the NFAT pathway and above mentioned genes in MTI101 sensitive MM cell lines could prove beneficial in understanding the determinants of sensitivity
to MTI-101 first in-vitro, and translationally but comparing the findings to the gene expression
from patients’ specimens. Being able to determine whether upregulated NFAT pathway along with
other SOCE pathway genes contributing to MTI-101 would be instrumental in stratifying patients
eligible to receive MTI-101. Furthermore, performing gene expression analysis on CD138+ cells
from bone marrow patients’ specimens, following determination of sensitivity to MTI-101 would
aid in identifying eligible patients for MTI-101 treatment.
We previously reported that the fibroblast bone marrow stroma cell line HS-5 is insensitive to
MTI-101, as was shown that MTI-101 does not induce Ca2+ influx or cell death. Furthermore,
Nair and colleagues reported that peripheral blood mononuclear cells (PBMCs) from healthy
individuals are not sensitive to MTI-101 parent drug HYD1 [6]. These findings although positive,
raises the question, what are absolute determinant of response to MTI-101 in cancer cells, and
what is the dose-limiting toxicity (DLT) to MTI-101. Future studies focusing on expression
profiling for insensitive cell lines or PBMCs to MTI-101, or even cancer cells that don’t respond
to MTI-101 could prove beneficial in understating what mediates MTI-101 effect. Moreover, MTI101 did not induce Ca2+ influx in HS-5 cell line, and based on previous reports that MTI-101
binds a surface complex containing CD44, along with a reduction in cleaved α 4 intergrin (VLA4) in H929-60-HYD1 resistant MM cell line, their still remains a gap in what is the upstream
activator of the SOCE pathway, and what are the other binding partners in MTI-101 complex, and
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future experiments on the binding partner to MTI-101 could aid in the delineation between MTI101-sensitive and insensitive cells [7,8].
Owing to this diversity in TRPC1 mode of activation, it is conceivable that MTI-101 activity could
be dependent on coupling STIM1 and TRPCs in MM cells. Consistent with this notion, we
observed that MTI-101-induced cell death is partially dependent on the expression of TRPC1/4/5,
suggesting that they participate in the complex formation with STIM1. We further report that in
an inactive state, and in absence of MTI-101, we failed to detect TRPC1 at the plasma membrane,
and the activation of the SOCE pathway by MTI-101 allowed TRPC1 trafficking and insertion
into the plasma membrane. TRPC1 recycling to and from the plasma membrane following SOCE
activation has been reported previously by De Souza and colleagues [9]. They reported that the
TRPC1 fast recycling is dependent on trafficking to the plasma membrane by Rab4 and the
internalization into Rab5-containing endosomes is an ARF6-dependent pathway. Future studies
determining the mechanism underpinning MTI-101-induced trafficking of TRPC1 to the plasma
membrane, for example the overexpression of Rab5 induced retention of TRPC1 in the sub-plasma
membrane TRPC1-containing vesicles [9].
The Ca2+-activated protease calpain 1 is associated with poor survival in MM patients in the
COMPASS dataset. Kaczmarek et al reported that TRPC5 is a calpain substrate as they showed
that the pharmacological inhibition of calpain I/II inhibited TRPC5, and is activated by calpain
truncation [10]; further, Verheijden and colleagues reported that TRPC6 contributes to calpain I
activation, and pharmacologically inhibiting calpain I or genetically knocking it down abrogated
TRPC6 effects on podocyte injury in the kidneys [11]. Other reports indicated that Ca2+ entry
through active TRPC1 activates calpain I in neurons and regulates axon outgrowth [12]. Our
findings indicated that MTI-101 treatment induces cleavage of TRPC1 and that TRPC1 is a
substrate for recombinant calpain I. In addition, pharmacological inhibition of calpains blocked
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MTI-101-induced calcium influx and cell death. Based on these data it is attractive to reason that
the calpain-dependent feed-forward loop is due to cleavage of TRPC1 either via induction of a
higher conductance or open probability of the channel. Future studies are required to determine
the functional consequence of TRPC1 cleavage on MTI-101-induced calcium and sodium entry.
Using a calpain consensus motif prediction software for TRPC1 (Group-based Prediction System
– Calpain Cleavage Detector GPS-CCD), we were able to identify 19 possible positions where
calpain is likely to induce cleavage [13]. Out of the 19 positions, position 249 (glutamic acid) is
shown to be a possible truncation site. Cleavage at E249 corresponds to truncation of ∼28 kDa,

and we identified a truncated fraction of TRPC1 of approximately 28 kDa. To address the TRPC1
calpain consensus site, transfecting MM cells with truncated mutant TRPC1, and test the cells
sensitivity to MTI-101 would determine whether these truncated TRPC1 fractions are capable of
forming channels, and whether they are able to a complex with STIM1.
Cleavage of TRPC1 was targeted in cells sensitive to MTI-101, while cleavage was not observed
in the stroma cell line HS-5. However, Ca2+-activated recombinant calpain I was able to cleave
TRPC1 from HS-5 derived lysates. These finding correlate with failure of MTI-101 to evoke a
calcium response in HS-5 stroma cells. Again, more studies are required to fully understand the
mechanism underpinning the MTI-101-induced trafficking of TRPC1 to the plasma membrane,
and its continuous activation leading to the sustained Ca2+ influx and cell death.
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agree to the following terms and conditions applying to this transaction. You also agree to
the Billing and Payment terms and conditions established by Copyright Clearance Center
(CCC) at the time you opened your Rightslink account.
LIMITED LICENSE
The AACR grants exclusively to you, the User, for onetime, non-exclusive use of this
material for the purpose stated in your request and used only with a maximum distribution
equal to the number you identified in the permission process. Any form of republication
must be completed within one year although copies made before then may be distributed
thereafter and any electronic posting is limited to a period of one year. Reproduction of this
material is confined to the purpose and/or media for which permission is granted. Altering or
modifying this material is not permitted. However, figures and illustrations may be
minimally altered or modified to serve the new work.
GEOGRAPHIC SCOPE
Licenses may be exercised as noted in the permission process
RESERVATION OF RIGHTS
The AACR reserves all rights not specifically granted in the combination of 1) the license
details provided by you and accepted in the course of this licensing transaction, 2) these
terms and conditions , and 3) CCC's Billing and Payment terms and conditions.
DISCLAIMER
You may obtain permission via Rightslink to use material owned by AACR. When you are
requesting permission to reuse a portion for an AACR publication, it is your responsibility to
examine each portion of content as published to determine whether a credit to, or copyright
notice of a third party owner is published next to the item. You must obtain permission from
the third party to use any material which has been reprinted with permission from the said
third party. If you have not obtained permission from the third party, AACR disclaims any
responsibility for the use you make of items owned by them.
LICENSE CONTINGENT ON PAYMENT
While you may exercise the rights licensed immediately upon issuance of the license at the
end of the licensing process for the transaction, provided that you have disclosed complete
and accurate details of your proposed use, no license is finally effective unless and until full
payment is received from you, either by the publisher or by the CCC, as provided in CCC's
Billing and Payment terms and conditions. If full payment is not received on a timely basis,
then any license preliminarily granted shall be deemed automatically revoked and shall be
void as if never granted. Further, in the event that you breach any of these terms and
conditions, or any of the CCC's Billing and Payment terms and conditions, the license is
automatically revoked and shall be void as if never granted. Use of materials as described in
a revoked license, as well as any use of the materials beyond the scope of an unrevoked
license, may constitute copyright infringement and the publisher reserves the right to take
any and all action to protect its copyright in the materials.
COPYRIGHT NOTICE
You must include the following credit line in connection with your reproduction of the
licensed material: "Reprinted (or adapted) from Publication Title, Copyright Year,
Volume/Issue, Page Range, Author, Title of Article, with permission from AACR".
TRANSLATION
This permission is granted for non-exclusive world English rights only.
WARRANTIES
Publisher makes no representations or warranties with respect to the licensed material.
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INDEMNIFICATION
You hereby indemnify and agree to hold harmless the publisher and CCC, and their
respective officers, directors, employees and agents, from and against any and all claims
arising out of your use of the licensed material other than as specifically authorized pursuant
to this license.
REVOCATION
The AACR reserves the right to revoke a license for any reason, including but not limited to
advertising and promotional uses of AACR content, third party usage and incorrect figure
source attribution.
NO TRANSFER OF LICENSE
This license is personal to you and may not be sublicensed, assigned, or transferred by you
to any other person without publisher's written permission.
NO AMENDMENT EXCEPT IN WRITING
This license may not be amended except in a writing signed by both parties (or, in the case
of publisher, by CCC on publisher's behalf).
OBJECTION TO CONTRARY TERMS
Publishers hereby objects to any terms contained in any purchase order, acknowledgement,
check endorsement or other writing prepared by you, which terms are inconsistent with these
terms and conditions or CCC's Billing and Payment terms and conditions. These terms and
conditions together with CCC's Billing and Payment terms and conditions (which are
incorporated herein) comprise the entire agreement between you and publisher (and CCC)
concerning this licensing transaction. In the event of any conflict between your obligations
established by these terms and conditions, and those established by CCC's Billing and
Payment terms and conditions, these terms and conditions shall control.
THESIS/DISSERTATION TERMS
If your request is to reuse an article authored by you and published by the AACR in your
dissertation/thesis, your thesis may be submitted to your institution in either in print or
electronic form. Should your thesis be published commercially, please reapply.
ELECTRONIC RESERVE
If this license is made in connection with a course, and the Licensed Material or any portion
thereof is to be posted to a website, the website is to be password protected and made
available only to the students registered for the relevant course. The permission is granted
for the duration of the course. All content posted to the website must maintain the copyright
information notice.
JURISDICTION
This license transaction shall be governed by and construed in accordance with the laws of
Pennsylvania. You hereby agree to submit to the jurisdiction of the federal and state courts
located in Pennsylvania for purposes of resolving any disputes that may arise in connection
with this licensing transaction.
Other Terms and Conditions:
v1.0
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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This agreement sets out the terms and conditions of the licence (the Licence) between you
and Springer Nature Customer Service Centre GmbH (the Licensor). By clicking
'accept' and completing the transaction for the material (Licensed Material), you also
confirm your acceptance of these terms and conditions.
1. Grant of License
1. 1. The Licensor grants you a personal, non-exclusive, non-transferable, world-wide
licence to reproduce the Licensed Material for the purpose specified in your order
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use, subject to the conditions below.
1. 2. The Licensor warrants that it has, to the best of its knowledge, the rights to
license reuse of the Licensed Material. However, you should ensure that the material
you are requesting is original to the Licensor and does not carry the copyright of
another entity (as credited in the published version).
1. 3. If the credit line on any part of the material you have requested indicates that it
was reprinted or adapted with permission from another source, then you should also
seek permission from that source to reuse the material.
2. Scope of Licence
2. 1. You may only use the Licensed Content in the manner and to the extent permitted
by these Ts&Cs and any applicable laws.
2. 2. A separate licence may be required for any additional use of the Licensed
Material, e.g. where a licence has been purchased for print only use, separate
permission must be obtained for electronic re-use. Similarly, a licence is only valid in
the language selected and does not apply for editions in other languages unless
additional translation rights have been granted separately in the licence. Any content
owned by third parties are expressly excluded from the licence.
2. 3. Similarly, rights for additional components such as custom editions and
derivatives require additional permission and may be subject to an additional fee.
Please apply to
Journalpermissions@springernature.com/bookpermissions@springernature.com for
these rights.
2. 4. Where permission has been granted free of charge for material in print,
permission may also be granted for any electronic version of that work, provided that
the material is incidental to your work as a whole and that the electronic version is
essentially equivalent to, or substitutes for, the print version.
2. 5. An alternative scope of licence may apply to signatories of the STM Permissions
Guidelines, as amended from time to time.
3. Duration of Licence
3. 1. A licence for is valid from the date of purchase ('Licence Date') at the end of the
relevant period in the below table:
Scope of Licence
Post on a website
Presentations
Books and journals

Duration of Licence
12 months
12 months
Lifetime of the edition in the language purchased
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4. 1. The Licensor's permission must be acknowledged next to the Licenced Material in
print. In electronic form, this acknowledgement must be visible at the same time as the
figures/tables/illustrations or abstract, and must be hyperlinked to the journal/book's
homepage. Our required acknowledgement format is in the Appendix below.
5. Restrictions on use
5. 1. Use of the Licensed Material may be permitted for incidental promotional use and
minor editing privileges e.g. minor adaptations of single figures, changes of format,
colour and/or style where the adaptation is credited as set out in Appendix 1 below. Any
other changes including but not limited to, cropping, adapting, omitting material that
affect the meaning, intention or moral rights of the author are strictly prohibited.
5. 2. You must not use any Licensed Material as part of any design or trademark.
5. 3. Licensed Material may be used in Open Access Publications (OAP) before
publication by Springer Nature, but any Licensed Material must be removed from OAP
sites prior to final publication.
6. Ownership of Rights
6. 1. Licensed Material remains the property of either Licensor or the relevant third party
and any rights not explicitly granted herein are expressly reserved.
7. Warranty

IN NO EVENT SHALL LICENSOR BE LIABLE TO YOU OR ANY OTHER PARTY OR
ANY OTHER PERSON OR FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL
OR INDIRECT DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, VIEWING OR USE OF THE
MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH
OF CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT
OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON
LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF
THIRD PARTIES), AND
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN.
8. Limitations
8. 1. BOOKS ONLY:Where 'reuse in a dissertation/thesis' has been selected the
following terms apply: Print rights of the final author's accepted manuscript (for clarity,
NOT the published version) for up to 100 copies, electronic rights for use only on a
personal website or institutional repository as defined by the Sherpa guideline
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(www.sherpa.ac.uk/romeo/).
8. 2. For content reuse requests that qualify for permission under the STM Permissions
Guidelines, which may be updated from time to time, the STM Permissions Guidelines
supersede the terms and conditions contained in this licence.
9. Termination and Cancellation
9. 1. Licences will expire after the period shown in Clause 3 (above).
9. 2. Licensee reserves the right to terminate the Licence in the event that payment is not
received in full or if there has been a breach of this agreement by you.

Appendix 1 — Acknowledgements:
For Journal Content:
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION
(Article name, Author(s) Name), [COPYRIGHT] (year of publication)
For Advance Online Publication papers:
Reprinted by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION
(Article name, Author(s) Name), [COPYRIGHT] (year of publication), advance
online publication, day month year (doi: 10.1038/sj.[JOURNAL ACRONYM].)
For Adaptations/Translations:
Adapted/Translated by permission from [the Licensor]: [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION
(Article name, Author(s) Name), [COPYRIGHT] (year of publication)
Note: For any republication from the British Journal of Cancer, the following
credit line style applies:
Reprinted/adapted/translated by permission from [the Licensor]: on behalf of Cancer
Research UK: : [Journal Publisher (e.g. Nature/Springer/Palgrave)] [JOURNAL
NAME] [REFERENCE CITATION (Article name, Author(s) Name),
[COPYRIGHT] (year of publication)
For Advance Online Publication papers:
Reprinted by permission from The [the Licensor]: on behalf of Cancer Research UK:
[Journal Publisher (e.g. Nature/Springer/Palgrave)] [JOURNAL NAME]
[REFERENCE CITATION (Article name, Author(s) Name), [COPYRIGHT] (year
of publication), advance online publication, day month year (doi: 10.1038/sj.
[JOURNAL ACRONYM])
For Book content:
Reprinted/adapted by permission from [the Licensor]: [Book Publisher (e.g.
Palgrave Macmillan, Springer etc) [Book Title] by [Book author(s)]
[COPYRIGHT] (year of publication)
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Other Conditions:
Version 1.3
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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